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Chapter I: Introduction 
The introduction is structured in four main sections. The first one reviews the 
pathological features of the Myocardial Infarction (MI), the unmet clinical needs and 
the strategies that are currently under investigation, focusing in particular on 
therapeutic angiogenesis. Thus, section two is a deep insight into the biological 
mechanisms of blood vessels growth, with a particular attention to the role of the 
Vascular Endothelial Growth Factor (VEGF). Section three gives a general overview of 
the several VEGF-delivery strategies to induce therapeutic angiogenesis with a 
conclusive deeper focus on the cell based gene therapy approach which ultimately 
leads to the aim of the thesis, described in section four. 
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1 Myocardial infarction: clinical needs and innovative treatments 
1.1 Cardiovascular ischaemic diseases: a general overview  
According to the last updated report published in 2014 by the World Health 
Organization (Global Health Estimates: Deaths by Cause, Age, Sex and Country 2000-
2012), in 2012 an estimated number of 17.2 M of people died because of 
Cardiovascular Diseases (CVD) (1). Among them, the major number of deaths, about 14 
M, were due to an ischaemic event (Cardiovascular Ischaemic Disease, CID), which is 
generally caused by a chronic atherosclerotic condition (2). Atherosclerosis defines the 
build-up of fatty deposits on the inner walls of the blood vessels, resulting in a 
progressive shortening of oxygen and nutrients to the downstream tissue (3). 
Depending from the affected district of the body, CID are divided in Peripheral Artery 
Disease (PAD, legs and arms), Coronary Artery Disease (CAD, heart) or cerebrovascular 
disease (brain, generally referred as stroke). CAD and stroke are the most severe 
conditions, resulting in about 30% of death during the acute phase. 
1.2 Ischaemic heart disease: current treatment and unmet clinical needs 
About 7.4 M of people die annually because of Coronary Artery disease (CAD), also 
known as Ischemic Heart Disease (IHD), making it the number-one cause of death 
globally. Although in developed countries the risk of death from CAD for a given age 
has decreased between 1980 and 2010 (1), mostly due to the prevention actuated to 
reduce some risk factor behaviours (smoking, lack of exercise, obesity, poor diet and 
excessive alcohol), severe morbidity and high mortality upon treatments are still 
common situations. In particular, management of Myocardial Infarction (MI), the most 
relevant disease in CAD, represents a major issue and, in most cases, current therapies 
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can only limit but not prevent the progression to an end-stage of Heart Failure (HF) (4). 
During MI, the shortage of oxygens and nutrients occurring in the downstream tissue 
upon a blockage in the coronary circulation leads to an ischaemic event and necrosis of 
the affected area. This event is responsible for the loss of cardiomyocytes, the 
contractile cells of the myocardium supporting the pumping of the heart, impairing the 
normal functionality of the organ. The severity of the clinical outcome depends on the 
extension and the location of the coronary blockage. Occlusions occurring in a minor 
coronary, or moderately in a major artery, result in a partial thickness damage of heart 
muscle, a condition known as NSTEMI (Non–ST-segment elevation myocardial 
infarction) accounting for about 30% of the total cases. On the other hand, STEMI (ST-
segment elevation myocardial infarction), which represents the other 70%, occurs by 
developing the complete occlusion of a major coronary artery, causing a whole 
thickness-damage of the cardiac wall. It is crucial to distinguish between the two 
conditions because although similar, the treatment is different. Surgical and non-
surgical neovascularization strategies aiming at restoring the blood flow to the 
ischemic tissue (such as Coronary Artery Bypassing Graft or Percutaneous Coronary 
Intervention) represent the first line treatments, together with pharmacological 
therapies such as antiplatelets, anticoagulants, beta-blockers, nitrate, statins, 
angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers. 
However, many patients still experience a negative outcome at long-term period. This 
is a direct consequence of the low capacity of human adult cardiomyocytes in re-
entering in the cell cycle and 
4 
 
 
Fig. 1 Myocardial infarction (MI). A) Normal heart with functional cardiomyocytes supported by an 
adequate functional micro-vasculature. B) The occlusion of the coronary circulation results in necrosis of 
the downstream myocardium with a rarefaction of capillary network, a consistent loss of functional 
cardiomyocytes in the infarcted area and a hypertrophic reaction of the survived cells at the border 
zone. C) Histological evidence of the microvascular damaged in a rat heart after successful coronary 
reperfusion following MI (No-reflow phenomenon). Figure modified from: Forte G., et al Stem Cell Rev. 
2013; O'Neill H.S., et al Adv. Mater. 2016; O'Farrell F.M. et al Nat. Rev. Cardiol. 2014. 
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proliferating, thus regenerating the damaged tissue (5). Hence, in case of a grave 
ischemic event the heart replaces the huge loss of cardiomyocytes with a connective 
fibrotic tissue, which is not contractile and displays inadequate elastic and electro-
conductive properties. To compensate, the remained cardiomyocytes at the border 
zone of the infarcted area undergo a hypertrophic process, which at long-term results 
in the disassembling of the sarcomere units and the consequent dysfunction of the 
organ. On the other hand, a spare destruction of the capillary network responsible for 
the exchange of oxygen and nutrients occurs in the affected area ( ) (6). Consequently, 
even in cases of re-established coronary circulation, incomplete or partial reperfusion 
of the ischaemic tissue is often observed and this disorder is known as no-reflow 
phenomenon (7). This continuous chronic situation is often associated with an increase 
in the size of the infarcted area and a faster progression to the end stage of heart 
failure (6). All these events are part of the post-infarct phase, known as ventricular 
remodelling that, in a long-term period, leads the heart to an end-stage of failure. 
While the current treatments (revascularization strategies and pharmacological 
therapies) aim on one hand to restore the coronary circulation and on the other hand 
to prevent the build of a new atherosclerotic plaque (8), the regeneration of the 
myocardium still remain an unmet clinical need (9). In order to restore completely the 
functionality of the infarcted myocardium, research has focus in finding novel 
strategies to replace the damaged tissue. 
1.2.1 Novel biological-based treatment strategies 
Since the early 90’s, the group of Anversa conducted pioneer studies to investigate the 
latent mitotic capacity of adult mammalian cardiomyocytes (10). In 2009, an elegant 
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study carried on at the Karolinska Institute in Stockholm confirmed that human adult 
cardiomyocytes undergo a renewing process at the rate of c.a 1% per year at the age 
of 25 decreasing until 0.45% at the age of 75 (5). This observation drastically switched 
the paradigm considering the heart a terminal differentiated organ and represented 
the demonstration of a concept that for long time has been rejected by a great part of 
the scientific community (11). However, the origin of the new cardiomyocytes is still 
highly debated (12). The concept of using “stem cell therapy” to remuscularize the 
damaged myocardium captured the attention of investigators, which focused in 
identifying the “optimal” stem cell source, such as satellite cells, able to colonize and 
differentiate in functional cardiomyocytes (13). The identification in the mouse heart 
of resident adult cardiac progenitor cells (CPC) opened the new perspective to isolate, 
expand and re-inject in loco a cell population already committed towards a mature 
cardiac phenotype (14). Moreover, some studies reported the recruitment and partial 
trans-differentiation in cardiomyocytes of bone marrow-derived mesenchymal stem 
cells (MSC) in the area of the infarction (15) further supporting the rationale that cell-
based therapies could be the solution for the heart repair. Nevertheless, the beneficial 
effects of injection of bone marrow–derived mononuclear cell (BMMNC) or MSC, 
although evident in preclinical animal models, became strongly controversial in the 
numerous clinical trials launched since the early 2000’s, hence questioning their real 
therapeutic potential (16). A recent study with 1 year follow-up coordinated by the 
University Hospital of Zurich demonstrated no effect of BM-MNC injection in 200 
patients affected by MI (17), further confirming the results of a previous independent 
study (18). Beyond the general poor cell survival, mainly due to inadequate delivery 
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strategies, serious doubts rose around the initial hypothesis of a direct contribution of 
the transplanted cells through an acquisition of cardiac phenotype (19). On the 
opposite, the rare poor improvements observed in some patients were often 
described as the results of cardioprotective/cardiorestorative effects triggered by 
factors secreted by the adult stem cell population, such as vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), 
insulin-like growth factor (IGF)-I, interleukin (IL)-1β and tumour necrosis factor (TNF)-α 
(20). These proteins are responsible for pro-angiogenic and anti-inflammatory stimuli 
associated with the reduction of scar and an amelioration of the overall cardiac 
functionality (21). This speculation found further support in a recent study performed 
in mice that deeper investigated the secretome profile of progenitor cells and the 
effects of a MSC conditioned media on myocardial infarction (22). Several groups 
developed trans-differentiation protocols to translate the cell therapy to a cell source 
with the unequivocal ability in differentiating in fully functional cardiomyocytes, like 
Embryonic Stem Cells (ESC) (23) or induced Pluripotent Stem Cells (iPSC) (24). 
However, the safety of these approaches still needs to be completely verified, and the 
usage of embryonic stem cells still brings unsolved ethical concerns (25).  
In conclusion, these findings changed the conceptual mechanisms through which the 
infarcted area might benefit from cell therapy. Research moved from cell-based 
remuscularization strategies towards a restoring of innate tissue regeneration 
processes triggered by paracrine factors (19). Therefore, several approaches, including 
molecular medicine and gene therapies, have been developed either as standard 
technique alone or combined with stem cell therapies, to activate or enhance such 
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physiological mechanisms. In this context, one of the most studied approaches is the 
induction of therapeutic angiogenesis through the in situ delivery of pro-angiogenic 
factors. 
1.3 Clinical need of therapeutic angiogenesis 
As previously mentioned, in the clinical context of MI, the extension of the affected 
area depends on several factors, among which time and efficiency of blood flow 
reinstatement are critical aspects. Notably, some patients experience a non-adequate 
restoration of perfusion, known as no-reflow phenomenon, despite a successful 
primary surgical/pharmacological intervention, which correlates with a faster 
progression to an end-stage of heart failure (6). Such effect seems due to a rarefaction 
and dysfunction of the microvascular circulation occurring in the ischaemic tissue (26). 
Therefore, after MI, growth of new capillaries from the ischaemic border zone into the 
affected myocardium appears to be crucial for rescuing myocardial areas (“Hibernating 
Myocardium” or HM), which are still viable but in a chronic condition of inadequate 
blood supply (Fig 2) (27). Physiologically, perfusion can be re-established by two 
different mechanisms: angiogenesis and arteriogenesis. Angiogenesis is a process that 
is induced per se by the ischemic event and is characterized by the sprouting of new 
blood vessels from the pre-existing ones. On the other hand, arteriogenesis refers to a 
transformation of smaller arterioles into bigger arteries; it occurs following a variation 
of the fluid shear stress in small arterioles, in response to a change in the pressure 
caused by the occlusion of an upstream artery. Recently it was shown that pro-
angiogenic stimuli occurring in the ischaemic tissue cause a back forward signalling 
which is responsible for the opening of  
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Fig. 2 Clinical need of therapeutic angiogenesis. A) In a condition of reperfused myocardium after MI, 
the rarefaction of the capillaries could generate a circumstance where cardiomyocytes are 
“hibernating”, namely still alive but with a reduced functionality due to the inadequate supply of 
nutrients. In this context, therapeutic angiogenesis could rescue survived CM by restoring microvascular 
network. B) In a condition of chronic ischaemia, when the patient is not a good candidate for current 
revascularization strategies, proangiogenic stimuli in loco could be exploited to open collateral arteries 
and re-establish the coronary circulation. Figure modified from: O'Neill H.S., et al Adv. Mater. 2016. 
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collateral arteries, namely tubes that are not functional in the physiological condition 
but become perfused following an ischaemic event (28). In this context, boosting the 
pro-angiogenic physiological response could be efficient in re-establishing the blood 
perfusion by inducing the growth of the new vessels as well as by triggering pro-
arteriogenic signalling (Fig. 2). In perspective, it could be used as standard therapy e.g. 
in some clinical cases which are not suitable candidates for the currently available 
revascularization strategies, or in combination with cell based or tissue engineering 
approaches.  
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2 Biological mechanisms of blood vessel growth 
2.1 Development of circulatory system 
The cardiovascular system is responsible for supplying oxygen and nutrients and 
removing metabolic wastes from the tissues; two organs complete these functions: the 
heart and the blood vessels, which are respectively the blood-pumping unit and the 
tubes of the system. Blood vessels are divided in five different tubes: arteries: I) and 
veins II) which are the biggest in size and bring the blood from the heart to the main 
compartments of the body and vice versa. Arterioles III) and venules IV) instead 
connect the larger vessels with the capillaries (V) that are responsible of the nutrients 
exchange. In order to adequately reach and cover all the organs of a healthy human 
being, the heart pumps about 7.5l of blood every day, within almost 100.000 km length 
of blood vessels. In the adult organism, only two districts are avascular: the crystalline 
in the eye and the hyaline cartilage; cells from all the other types of tissues strictly 
relied on vascularisation. In tissues with a high metabolic demand, such as the 
myocardium, skeletal muscle or bone marrow, the distance from the cells to the 
closest capillary is rarely more than 200 µm (29) (30). Such a dense complex structure 
is the result of dynamic changes in assembling, expansion and remodelling of blood 
vessels, which start during the embryogenesis, and is maintained during all the life in 
response of pathophysiological stimuli. 
2.1.1 Vasculogenesis 
 In vertebrates, the development of the cardiovascular system is one of the first events 
that take place during the organogenesis and starts with the biological process of 
vasculogenesis, during which mesoderm derived endothelial precursors  assembly in 
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the primitive vascular network.  In the past years, many studies on transgenic mice 
models helped in determining the key pathways responsible for the guide of de novo 
blood vessel formation during gastrulation, such as Vascular Endothelial Growth Factor 
(VEGF) and its receptor flk-1 (VEGFR-2). Notably, VEGF knockout is lethal in the early 
stage of the gastrulation also in a heterozygosis showing that this signal is 
haploinsufficient (31). Equally, mutation of flk-1 is fatal within the first 9 days of 
development due to the inability of the embryo in forming blood vessels and 
hematopoietic compartment (32). Morevoer, Flk-1 is an early marker of the primitive 
angioblasts and appears on a subset of Brachyury-positive cells in the primitive streak. 
It has been shown that these cells are able to give raise to either endothelial or 
hematopoietic lineages (33). In response to a basic Fibroblast Growth Factor (bFGF) 
and bone morphogenetic protein 4 (BMP-4) mediated signals, hemangioblasts migrate 
in the extra-embryonic ectoderm yolk sac and start to aggregate in clusters (blood 
islands) where the inner cells proceed towards a haematopoietic lineage whereas the 
external ones fuse, forming the first capillary plexus. On the other hand, mesoderm 
progenitors that disperse intra-embryonic, driven by sonic hedgehog (SHH), Notch and 
VEGF signals, assemble the dorsal aorta and the cardinal vein. These two distinct 
events together establish the initial primitive vascular network (34), which then 
undergoes expansion, remodelling and stabilization to form a mature circulation 
during the process named angiogenesis. VEGF is the main regulator of this event, but 
angiopoietins, platelet-derived growth factor (PDGF-B) and Transforming Growth 
Factor (TGF-B) are critical for the mobilization of endothelial cells (hence the growth of 
new capillaries) and the recruitment of pericytes that are responsible to stabilise the 
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newly formed blood vessels (35). Notably, most of the signalling pathways governing 
the assembling and the vasculature expansion during embryo development are 
recapitulated in a situation of neo-angiogenesis in the adult (36). 
2.1.2 Arterial-venous specification 
As vessels begin to remodel and grow towards the different compartment of the body, 
they simultaneously need to be specified as arterial or venous phenotype, which are 
interconnected but maintain different structures and functions. In fact, unlike veins, 
arteries are subjected to high blood pressure of systole; therefore, a thick layer of 
smooth muscle cells and connective tissue surround their endothelium. Based on this 
concept, initially it has been thought that hemodynamic forces could drive 
specification of the arterial-venous phenotype soon after the starting of the circulation 
in the yolk sac. Consistent with this hypothesis, Le Noble and colleagues showed that 
manipulation of the blood flow in the yolk sac of the chick causes simultaneously the 
downregulation the arterial marker EphrinB2, and the conversion to venous 
endothelial phenotype (EphB4) (37). 
On the other hand, interfering with the Notch-Gridlock signalling in zebrafish before 
the onset of a functional circulation causes a progressively reduction of the artery 
regions, simultaneously expanding area of the vein, shown by an increase in expression 
of EphB4 receptor (ephb4) and contiguous decrease of the arterial marker Ephrin-B2 
(38). Moreover, it is well-known that in the mice embryo the complementary and 
mutually expression of EphrinB2 and EphB4 on angioblasts occurs already during early 
stage of vasculogenesis (39). Another independent study showed that the vascular 
plexus already contains a mix of angioblasts positive for Neuropilin1 (NP1) or NP2 
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expression, which are specific markers for arterial or venous phenotype respectively 
(40). These studies taken together suggest a prior key role of a genetic selection for the 
specification of arterial-venous phenotype, which however can be further shaped by 
haemodynamic forces during the early vasculature expansion.  
2.2 Angiogenesis 
Angiogenesis is the biological process during which new blood vessels grow and 
expand from the pre-existing vasculature. It occurs throughout the entire life of the 
organism: starting during the early phase of embryo development until the old age. 
During embryogenesis, angiogenesis is responsible for the expansion and maturation 
of a functional circulatory system as well as is essential to provide fundamental 
morphogenic instructions for the correct development of some organs such as liver 
and bone (41). However, in the adulthood most of the blood vessels remain in a 
quiescent state with some physiological exceptions like in the placenta during the 
pregnancy, in the cycling ovary and the wound healing process (42). Nevertheless, all 
the endothelial cells maintain their ability in re-entering in the cell cycle and 
proliferating in response to proangiogenic stimuli triggered by specific growth factors. 
The mechanisms occurring during the angiogenesis process can be summarize in two 
main steps: I) tube and lumen formation and II) blood vessel maturation and 
stabilization. Mural cells (either pericytes or smooth muscle cells), play a key role in 
both phases by surrounding quiescent blood vessels and cross-talk with endothelial 
cells modulating their proliferation and survival. In response to a pro-angiogenic 
stimulus they detach from the endothelium and degrade the basement membrane, 
through secretion of Matrix Metalloproteinases (MMPs), allowing the migration of the 
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endothelial cells. Subsequently, mural cells are recruited through a Platelet-derived 
Growth Factor-B (PDGF-B) gradient on the wall of the newly formed blood vessel 
guaranteeing the maturation and stabilization of the vessels by depositing new ECM to 
restore the basal membrane. Formally, by definition a new vessel is stable when 
becomes independent from the pro-angiogenic stimulus (42). Angiogenesis is a process 
tuned by balanced secretion of different growth factors; therefore, once this balance is 
lost, this process can became a severe pathological condition such as in intraocular 
neovascular disorders, immunogenic rheumatoid arthritis and psoriasis (36). 
Moreover, solid neoplasia benefits of an uncontrolled and leaky angiogenesis to 
deliver nutrients in the core of the mass which otherwise would became necrotic. 
Several families of different growth factors have been identified in being able to 
stimulate the proliferation of endothelial cells such as VEGF, FGF and HGF (43). 
Nevertheless, vascular endothelial growth factor family predominantly represents the 
master regulator of angiogenesis process. 
2.2.1 Vascular endothelial growth factor  
VEGF has been identified for the first time in 1983 as a microvascular permeability 
protein in the guinea pigs, hamsters, and mice tumour ascites fluids (44); several years 
later, Ferrara and Henzel purified from a medium conditioned by bovine pituitary 
follicular cells a novel growth factor specific for endothelial cells (45). In mammals the 
VEGF family includes 5 members (VEGF-A, -B, -C, -D and the Placenta Growth Factor) 
and is part of the PDGF superfamily growth factors, which are secreted as dimeric 
proteins (Fig. 3).  
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Fig. 3 Structure and interactions of VEGFs with VEGFRs and their neuropilin (NRP) co-receptors. The 
arrows indicate the varying specificities of VEGF growth factors bind to their receptors. The N-terminal 
and C-terminal of VEGF-C and VEGF-D can be processed to interact with VEGFR-2. The binding of the 
dimeric VEGF ligands stimulates receptor dimerisation with a consequent autophosphorylation, 
triggering the downstream signalling. In addition to the five VEGF members known in mammals, other 
two VEGF homologues have been identified:  one produced by Orf viruses (VEGF-E) and one isolated 
from snake venom (VEGF-F). Figure modified from: Lohela M., et al Curr. Opin. Cell. Biol. 2009. 
 
VEGF-A is the main family member responsible for mitosis and migration of endothelial 
cells, also functioning as a vasodilator through a nitrox oxide signal cascade; on the 
opposite, VEGF-B has a less predominant role in triggering pro-angiogenic signals and 
is rather involved in preservation of existing blood vessels (46). VEGF-C and -D are 
mainly responsible for the development and repair of the lymphatic circulatory 
system; it has been shown that VEGF-C is required for sprouting of the first lymphatic 
vessels from embryonic veins and VEGF-C-/- in mice results to be lethal at a prenatal 
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stage (47). Moreover, VEGF-C can also modulate the vascular permeability and 
promotes the growth of blood vessels. (48). PlGF is mainly express by the placental 
trophoblast during embryogenesis and is important for vasculogenesis; nevertheless, it 
plays a role as well in regulating angiogenesis response during ischemia, inflammation 
and wound healing. Interestingly, secretion of PlGF is associated with a promotion of 
atherosclerotic intimal thickening and macrophage accumulation (49). 
2.2.1.1 VEGF receptors  
The various VEGF ligands interact with different affinity and defined specificity with 
three transmembrane tyrosine kinase receptors (VEGFRs): I) VEGFR-1 also known as 
fms-like tyrosine kinase 1 (Flt-1), II) VEGFR-2 defined as human kinase insert domain 
receptor (KDR)/mouse fetal liver kinase 1 (Flk1) and III) VEGFR-3 described as fms-like 
tyrosine kinase 4 (Flt4) (Fig. 3). All VEGFRs have an extracellular portion consisting of 7 
immunoglobulin-like domains, a single transmembrane spanning region and an 
intracellular portion containing a split tyrosine-kinase domain. Interaction with the 
ligand causes the dimerization and activation through transphosphorylation signal. 
Beyond the Tyrosine Kinase Receptors (TKRs), Neuropilin 1 and 2 (NRP1 and NRP2), 
originally identified as semaphorin receptors, have also affinity for specific VEGF 
isoforms and they function mostly as co-receptors rather than directly transducing the 
signal (50). For example, NRP1 selectively enhances VEGF-A binding to VEGFR-2, by 
presenting the protein to the receptor, increasing the downstream signal (51). 
Moreover, in the cornea has been identified a soluble form of VEGFR-1 (sVEGFR-1), a 
VEGFR-1 splice variant having a potent anti-angiogenic activity, which contributes in 
maintaining the area avascular (52). While PlGF/VEGF-B and VEGF-D bind selectively 
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VEGFR-1 and VEGFR-3 respectively, receptor specificity of VEGF-C is regulated by 
proteolytic processings (53); VEGF-A displays high affinity for both VEGFR-1 and VEGR-
2. Signaling of VEGF-A through VEGFR-2 is the major pathway that activates 
angiogenesis by inducing the proliferation and migration of endothelial cells (54).  
2.2.1.2 Role and regulation of VEGF-A isoforms 
VEGF-A is encoded in humans by the VEGFA gene located on the chromosome 6p21.3 
which is governed by upstream factors include oxygen tension through the signal 
triggered by the Hypoxia inducible factor (HIF), beyond several cytokines, chemokines 
and growth factors. The gene contains 8 exons separated by 7 introns; the alternative 
splicing occurring for exons 6a and 7 results in the generation of four principal 
isoforms, having 121, 165, 189, and 206 amino acids, respectively, after the cleavage of 
the signal sequence (VEGF121, VEGF165, VEGF189, VEGF206). Less frequent splice variants 
have been recently identified, including VEGF145, VEGF183, and VEGF162 (55). Moreover, 
in human it has been also reported a second category of isoforms generated by a distal 
splice-site selection (DSS) of the exon 8 which paradoxically results in a generation of 
anti-angiogenic VEGFxxxb versions (56). VEGF isoforms are typically secreted as 
cysteine linked antiparallel dimers. Binding to the VEGFRs is mediated at the exon 3 
and 4 (VEGFR1 and 2 respectively), whereas the exons 6 and 7 contain sequences of 
basic amino acids, (heparin binding domain, HBD) which are responsible for the 
interaction of the VEGF with heparan-sulphate proteoglycans (HSPGs). Importantly, 
the exon 7 contains also some regions important for the binding with NRP1. Since the 
splicing involves these sequence of the protein, isoforms VEGF121 (which lacks both the 
exons 6 and 7) and VEGF165 (where the exon 6 is absent) display no- or reduced 
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interaction with extracellular matrix HSPGs e.g. perlecans and agrins, as compared to 
the longer versions 189 and 206 (57). VEGFs bind to the ECM close to the producing 
cells and diffuse around, forming a spatial gradient, which is responsible of driving the 
growth of blood vessels. Larger VEGF isoforms that tightly bind the ECM show steeper 
gradients, suggesting that heparin interactions per se slow the molecule diffusion. 
Nevertheless, computational studies on VEGF diffusion in vivo demonstrated that ECM 
sequestration alone could not be the responsible for generation of the protein 
gradient. This process is rather controlled by several balanced biological events 
including VEGF cleavage or degradation and sequestration on cell surface by 
membrane HSPGs (e.g. syndecans) (58). In this context, VEGF189/206 might represent 
storage isoforms of the growth factor, which can be released after specific pro-
angiogenic cleavage process such as the proteolytic cascade of plasminogen activation 
(59). Importantly, several studies suggested that VEGF165, due to the intermediate 
ECM-binding properties and the affinity with the NRP1 has the ideal characteristics of 
bioavailability and biological potency (59). Remarkably, expression of only VEGF120 
(isoforms in mice are one amino acids shorter than in human) in mice resulted to be 
lethal prenatally, with a general reduced vascular complexity, leaky vessels because of 
poor pericytes coverage and ischemic cardiomyopathy (60). In addition, also mice 
expressing VEGF188 showed impaired angiogenesis with an excess of thin and 
disorganized vascular branches and several muscle disorders, resulting in affected 
growth and poor survival (60). On the other hand, homozygotes expression restricted 
to VEGF164 displayed a normal vessel phenotype with apparently any problem in 
survival (61).  
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2.2.2 Mechanisms of blood vessel expansion 
Angiogenesis can occur mainly through two different mechanisms: sprouting or 
intussusception. High debate still exists around the recruitment of bone marrow 
derived cells (BMCs) or circulating endothelial progenitor cells and their incorporation 
into the growing vessels (a process known as “postnatal vasculogenesis”) (62). 
Sprouting has been the first hypothesized and observed mechanism of blood vessel 
growth, occurring in response to a gradient of VEGF; the sequential steps of branching 
and the molecular mechanisms behind have been extensively investigated. As 
previously mentioned, in the adult under physiological conditions the blood vessels are 
maintained in a quiescent state; vascular homeostasis and survival are triggered by an 
autocrine endothelial cell VEGF-mediated signal (63). Moreover, endothelial cells are 
equipped with a system that represses their proliferation while allowing them in 
responding promptly to proangiogenic stimulus; this event is controlled mainly by the 
cross talk at the gap junctions of endothelial cells via the Angiopoietin (ANG)–Tie 
signalling. Briefly, mural cells secrete ANG-1, which clusterises the Tie2 receptor in a 
Trans configuration at the gap junctions of two adjacent endothelial cells, transducing 
pro-survival and anti-mitotic signal. On the opposite, the pro-angiogenic signals causes 
the release of ANG-2 from pericytes as well as from intracellular storage of endothelial 
cells, that acts as competitor of ANG-1, liberating Tie2, resulting in migration and 
proliferation signals (64). Branching and migration of the new blood vessel towards the 
source of the pro-angiogenic stimulus is a process that is guided by so called tip cell, 
which tests the environment with extruded filopodia, providing guidance cues (65). 
Following the angiogenic signalling at the onset of the sprouting, pericytes start to 
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degrade the basement membrane that surrounds quiescent blood vessels, liberating 
the endothelial cells (66). The process is actuated through secretion of 
metalloproteinases (MMPs) and is further controlled by the tip cells during the growth 
of the new tube (Fig. 4A). Importantly, extracellular matrix degradation also liberate 
pro-angiogenic growth factors (67). Sprout elongation and lumen formation is 
supported by the proliferation of stalk cells, which follow the tip guide. Selection of the 
tip cell and the subsequent specification of the next stalk endothelial cells is a process 
that is fine regulated by the Notch pathway. 
 
Fig. 4 Sprouting angiogenesis and tip-stalk cells regulation. A) VEGF stimulation causes the activation of 
endothelial cells (EC), which start to degrade the basement membrane. Pericytes detach from the 
vascular structures, allowing EC to migrate and elongate the new blood tube. B) Selected tip cells 
prevent the adjacent endothelial cells in acquiring tip features through the Notch/Dll4 lateral inhibition 
pathway, which is responsible for suppression of VEGFR2 and concomitant activation of cell cycle. Figure 
modified from: Potente M., et al Cell 2011. 
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In particular, VEGF signal on tip cells stimulate the expression of Dll4, activating the 
notch signalling on the adjacent cells. In response, notch supresses the tip cell 
phenotype in the stalk cells by decreasing the expression of VEGFR2 and increasing 
VEGFR1. In contrast, tip cells receive high JAGGED1 signal, a second ligand for notch 
with opposing functional roles in the vasculature, which maintaining the high 
expression of NRP1 and VEGFR2 (68). Selection of the tip cell depends on small 
differences in the expression or activity of VEGFR2 on endothelial cells or 
microenvironmental discrepancy in the concentration of VEGF, which could give an 
initial advantage to some individual cells to become the tip (Fig.4B) (69). The end step 
of the sprouting angiogenesis includes contact between tip cells from different sprouts 
to form new vessel circuits, and lumen formation that can occurs through different 
mechanisms such as cell hollowing (70). After the structure of the new vessel is 
established, the process of maturation must start (explained more in detailed in the 
next paragraph). So far, most of the knowledge about molecular mechanisms 
regulating angiogenesis have been studied in and refereed to the sprouting model.  
Nevertheless, the alternative vessel-growth process known as intussusception, takes a 
significant part in patho-physiological process, including cancer and embryogenesis 
(71) (72). Moreover, it has been observed that upon VEGF overexpression in rodent 
models, intussusception is the predominant mechanism through which angiogenesis 
occurs (73). It consists in the longitudinal splitting of two blood vessels from an existing 
one and occurs through the formation and subsequent fusion of aligned transversal 
holes within the blood vessel wall (Fig. 5). These gaps are known as vessel pillars and 
are considered the hallmarks of the intussusception mechanism. The formation 
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includes 4 consequential steps during which I) activated  endothelial cells start to 
protrude an intralumen process towards the opposite vessel wall, until a contact is  
established with and opposite protrusion; then a perforation occurs II) and the 
interstitial hole is immediately invaded by perycites III); through the deposition of 
extracellular matrix the pillar is re-shaped until it fuses with the close one, resulting in 
the splitting of the vessel (Fig. 5).  
 
Fig. 5 Morphogenic features of pillar formation. A–D) 3D graphic reconstruction of transluminal pillar 
formation. A*–D*) 2D transversal images of the relatives events (A)–(D). Endothelial cells (EC) on the 
opposite sides of a capillary protrude into the lumen until they make contact with each other. The 
formation of endothelial junctions reinforces and maintains the contact until the endothelial bilayer is 
perforated centrally. Fibroblasts (Fb) and pericytes (Pr) invade the newly formed pillar being invaded 
and start todeposit collagen fibrils (Co). BM, basement membrane. Figure modified from: Djonov V., et 
al. Cell Tissue Reearch 2003 
 
Induction of pillar formation is an aspect that still needs to be fully elucidated, 
although recent evidences showed that haemodynamic variations occurring in areas 
characterized by low shear stress and turbulent flow conditions play a key role (74).  
2.2.3 Maturation process 
Upon activation of endothelial cells and the consequent growth (or split) of the 
capillary network, the newly formed blood vessels need to mature in order to become 
persistent (75) and acquire tissue specific differentiation adapting the local 
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homeostatic demands (76). Recruitment of mural cells surrounding the new capillaries 
is a fundamental step for vessel maturation. Pericytes are mainly guided by the 
adequate secretion of PDGF-BB from endothelial tip cells that acts as chemoattractant, 
stimulating the proliferation and migration of the mural cells (77). Notably, mice 
lacking of pdgfβ or pdgfrβ display affected pericytes function resulting in persistent 
endothelial proliferation and vascular abnormalities with consequent bleeding (78). 
Once the pericytes take contact with the wall of the blood vessel, they induce 
endothelial differentiation and growth arrest by both cell-cell direct interactions and 
expression of paracrine factors. In particular, TGF-β is important for the deposition of 
ECM around the blood vessel to reconstitute the basement membrane, an event that 
is crucial for the stabilization process, and acts as autocrine factor to stimulate the 
proliferation of mural cells (79). Loss of function of TGF-β receptor 2 in mice results in 
vessel instability due to the affected pericytes development (79). Another pathway 
that has been shown to be critical for endothelial cells/pericytes interaction is the 
EphrinB2 expression, necessary to guarantee the anchor of mural cells on the vessel 
wall (80). Pericytes can also be recruited by an indirect mechanism through the action 
of immuno-cells. It is well-known that populations of bone marrow (BM)-derived 
mononuclear cells also are recruited to the sites of angiogenesis in adult tissues, 
triggering pro-angiogenic effects by secreting paracrine factors (81) (82). In particular, 
a population of monocytes, expressing both CD11b and the NRP1, stimulate pericytes 
and smooth muscle cell recruitment by secreting transforming growth factor-β (TGF-β) 
and platelet-derived growth factor-BB (PDGF-BB) (83), leading also to normalization of 
tumour vessels and inhibiting tumour growth (84). In this context, our group recently 
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demonstrated that increasing doses of VEGF negatively regulated vascular stabilization 
in a dose-dependent fashion, without affecting pericytes recruitment and maturation, 
but rather by directly inhibiting endothelial expression of the NRP1 ligand 
Semaphorin3A (Sema3A) and the NEM/TGF-β1 paracrine axis (85). 
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3 VEGF-based strategies for therapeutic angiogenesis 
3.1 First generation of VEGF delivery approaches and limitations: transgene 
expression efficacy, duration and dose 
The concept of delivering VEGF to induce therapeutic angiogenesis rose two decades 
ago as a novel and promising strategy to treat ischaemic limb, as largely supported by 
numerous preclinical studies. In two independent pilot trials in patients suffering of 
peripheral arterial disease, the arterial or intramuscular injection of a DNA plasmid 
harbouring VEGF165 gene resulted in angiogenesis and collateral vessel development 
respectively (86) (87). First evidences that delivery of proangiogenic factors could bring 
benefits to patients affected by congestive heart failure were reported in 1998. The 
study involved the injection of a DNA plasmid containing the gene for the VEGF (88).  
In parallel, Schumacher and colleagues demonstrated that the administration of 
recombinant human FGF in proximity of the site of anastomosis, provided 
revascularization of affected tissue by promoting capillary growth from the area of 
injection towards the periphery (89). Based on these encouraging results, several 
clinical trials started with the aim to confirm the initial observations. First-generation 
studies involved the direct injection of the recombinant protein or a gene therapy 
strategy based on the delivery of naked DNA or the use of adenovirus to overexpress 
the factor in situ (Fig. 6A). The VIVA (VEGF in Ischaemia for Vascular Angiogenesis) trial 
was the initial attempt to investigate the efficiency of injecting the recombinant 
protein in patients with CAD. Unfortunately, although safe, the study was stopped in 
phase II because the proved inefficacy of the treatment, most likely due to the very 
short half-life of the protein and the insufficient myocardial uptake (90). It was clear 
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that most of these limitations could be overcome by providing to the myocardium the 
VEGF-gene instead of the recombinant protein (91). Nevertheless, two clinical trials, 
EUROINJECT-ONE and NORTHERN performed on patients affected by stable severe 
ischaemic heart disease with no other options, showed no effects of naked VEGF165  
plasmid injection at long-term time points, despite some benefits in terms of 
myocardial perfusion were reported at 3 months upon the treatments (92) (93). While 
safe and relative low cost, the efficiency of the DNA uptake is poor. Moreover, 
preclinical studies showed that the duration of the expression of the gene delivered in 
form of DNA naked plasmid is limited to the first two weeks (91), which might be too 
short to induce the stabilization of the neovasculature, as previously mentioned, could 
affect. Of note, taking advantage of a transgenic system for conditional switching of 
VEGF, an elegant study showed that switching off the expression before 4 weeks 
caused a reproducible regression of the newly formed blood vessels (94). Two 
additional studies failed as well in achieving convincing clinical benefits, although they 
were designed to improve the VEGF plasmid activity by mobilizing putative angiogenic 
precursor cells from the bone marrow or by FGF-2 co-delivering (91). Similar 
discouraging results were registered in the KAT angiogenesis trial, investigating the 
effects of the injection of adenoviral vector harbouring VEGF165 gene (95); remarkably, 
same outcomes were obtained in patients treated with a different isoform of VEGF 
(121) or different members of FGF family.  The main reason for the failure of the first-
generation adenoviral vectors is their inflammatory and immunogenic potential that, 
in addition to several safety concerns, limits also the time expression of the transgene 
in vivo at maximum two weeks (96) (97). It is important to highlight that the majority 
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of clinical trials have been conducted mainly on severely affected patients at an 
advanced stage of the disease, who might not have the capacity to respond optimally 
to the therapies. Moreover major cardiac adverse events, mortality and other very 
challenging clinical end points have been used in relatively small patient populations. 
In the next studies, it might be useful to enrol less severely affected patients using also 
more informative read out (98). However, taken together, the results from human 
studies suggest that the different approaches used in delivering or expressing the VEGF 
are not efficient in achieving a level of expression able to trigger the therapeutic effect 
(96). On the other hand, animal studies showed that high and uncontrolled over-
expression of VEGF might induce the growth of angioma-like vascular tumours. Such 
events have been observed in the myocardium (99) (100), but also in skeletal muscle 
(101) (102), subcutaneous fat (103) and liver (94). These preclinical experimental 
results suggest the existence of a therapeutic window for VEGF gene delivery with 
lower doses being inefficacious and higher ones causing aberrant vascular growth 
(104). Moreover, since VEGF remains tightly localized in tissue after being secreted, as 
already discussed in the previous chapter, this therapeutic window of VEGF does not 
depend on the total dose administered, but rather on its level of release in the 
microenvironment. This biological concept has been elucidated and elegantly proved 
by the group of Helen Blau, taking advantage of a well-characterized cell-based 
platform for controlled gene delivery, in which clonal populations of transduced 
myoblasts were used to homogeneously express specific VEGF doses in vivo (102). 
Although observed only animals, these findings add a level of complexity in setting the 
approach for therapeutic angiogenesis, stating that an optimization is needed not only 
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on the efficacy and on the duration of VEGF expression but also on the level that is 
produce by the single cells.  
 
Fig. 6 VEGF delivery approaches. A) Direct endocardial/Intracoronary injection of recombinant VEGF or 
adenoviral vectors or naked-DNA plasmid harbouring VEGF were among the first strategies used to 
induce therapeutic angiogenesis in the myocardium. B) Novel biomaterial-based approaches rely on the 
possibility to link the VEGF to ECM protein fibers assembled in form of porous scaffold (e.g. collagen 
sponge) and delivered epicardially. Upon implantation, the VEGF migrates and diffuses in the 
underneath myocardium. Alternatively, VEGF can be add to hydrogel compositions and delivered 
directly into the myocardium via epicardial or catheter-based endocardial injections. Figure modified 
from: O'Neill H.S., et al Adv. Mater. 2016 
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3.2 New technologies and alternative approaches 
Besides the canonical gene therapy strategies, investigators attempt in finding new 
methods to deliver VEGF at a sustained level for an adequate time. An interesting 
approach to improve the efficacy of the therapeutic angiogenesis that is now in phase I 
clinical trial is represented by the possibility to increase the expression of the 
endogenous VEGF gene through the use of zing-finger (ZFP) proteins targeting 
activators on the gene promoter (105). Another possibility is to take advantage of the 
numerous drug delivery systems (DDS) that have been recently developed, including 
the possibility of enriching scaffolds, or trapping proteins in micro or nanoparticles. In 
order to increase the half-life of the protein and to localize its diffusion, in this context 
it is crucial to optimize the loading capacity, the distribution of the protein, the binding 
affinity that allows an adequate release profile and the ability to maintain the protein 
stability and bioactivity. (106). Loading of VEGF on scaffolds is the most studied 
strategy and so far, many different biological materials such as hydrogels made of ECM 
proteins such as collagen and fibrin have been tested as delivery system alone or in 
combination with functionalizing sequences to increase the interaction or to better 
control the release of the VEGF (106). Hydrogels are particularly advantageous as 
carrier systems because they are structurally similar to the tissue extracellular matrix 
(ECM) and can be designed to degrade in a timely fashion that coincides with the 
angiogenic process (107). Our lab recently optimized a fibrin platform for controlling 
delivery of recombinant VEGF, by fusing to the N-terminal of Murine VEGF164 a 
sequence derived from α2-plasmin inhibitor (α2-PI1–8), which is a substrate for the 
coagulation factor XIIIa, to allow its covalent cross-linking into fibrin hydrogels and 
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release only by enzymatic cleavage (108). This approach resulted in a gradual release 
of the protein in vivo with a subsequent sustained expression of the protein over the 
entire 4 weeks. 
Although promising, biomaterial mediated delivery of VEGF reacquires deeper 
investigation of the releasing profile in vivo, since this approach rely mostly on the 
reabsorption of the scaffolds occurring mainly by the enzymatic digestion triggered by 
the cells of the innate immunoresponse (109). To date, gene therapy is still the most 
affordable and suitable strategy to be tested in humans (91). In this context, the 
development of adeno-associated viral vectors (AAV) could represent a step forward in 
the clinical setting of therapeutic angiogenesis for cardiovascular disorders. This 
system in fact displays several advantages as compared to previous gene therapy 
methods, including no immunogenicity, hence no inflammatory response at the site of 
injection, and the capacity to transduce cells at high multiplicity of infection. It is 
reasonable to expect that such viral vectors will play a central role in the future not 
only restricted at the cardiovascular medicine field. (110). First preclinical 
investigations already showed a vascular regeneration in a clinical relevant animal 
model of ischemic hind limb by delivery of AAV expressing conditionally silenced VEGF 
(111). 
3.3 Cell-based delivery  
An effective strategy to control and optimize the expression of a transgene is 
represented by the possibility to exploit alive biological material as delivery platform, 
by using an autologous cell population previously modified genetically in vitro to over-
express the VEGF. The cell-based gene therapy has the potential to address some of 
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the critical issues that limit the efficacy of VEGF gene therapy: the procedure of DNA 
uptake can be controlled and optimized in vitro and the approach guarantees a 
sustained expression of the protein if the cells are able to engraft permanently in the 
host tissue. In this context, the use of VEGF-expressing myoblasts has been extensively 
investigated and optimized to treat ischaemia and several preclinical studies showed 
their ability in integrating in the host tissues inducing robust and stable angiogenesis in 
skeletal muscle and in the myocardium (112) (113). More recently, several groups, 
including our, translated this approach to endothelial progenitor and mesenchymal 
stromal cells from bone marrow or adipose tissue (114) (115) (116) (117). The use of 
stromal cells as delivery platform offers several advantages for a cardiac application 
compared to myoblast: I) myoblast transplantation in the heart causes arrhythmias 
due to their inability to electrically integrate with the host myocardium; II) the 
production of synergistic paracrine factors by the delivered progenitors addresses 
several pathophysiological processes including inflammation and scar deposition as 
previously discussed. To date, it is well accepted that adipose derived mesenchymal 
stromal cells represented an “optimal” cell source as drug delivering system for cardiac 
applications (118). Studies reported an increased angiogenic response in both 
ischaemic skeletal muscle and myocardial infarction treated with MSC genetically 
modified with AAV (115) or baculovirus (114) respectively to over-express VEGF. 
Recent data from our group showed that VEGF release from retrotransduced human 
adipose tissue-derived MSC induced stable angiogenesis in both normal and ischemic 
myocardium, and prevented deterioration of cardiac function after coronary artery 
ligation (119). Nevertheless, besides functional angiogenesis, delivery of VEGF resulted 
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also in the spot formation of aberrant structures due to the uncontrolled expression, in 
line with what has been reported by our and other groups (119).  
 In order to have a precise control over the microenvironmental distribution of level 
expression in vivo, we recently developed a high-throughput, Fluorescence Activated 
Cell Sorting (FACS)-based technology to identify and purify cells expressing a specific 
range of VEGF level (120). This was achieved by linking VEGF expression to that of a 
FACS-quantifiable syngenic cell surface marker (truncated CD8a), so that the amount 
of CD8 on the cell surface reflects the level of VEGF secreted. Taking advantage of this 
technology, we generated purified populations of bone marrow- and adipose-derived 
mesenchymal progenitors expressing specific VEGF levels (116). Remarkably, the 
injection of purified VEGF expressing cells in skeletal muscle (121) and in the heart 
induced robust angiogenesis preventing at the same time the formation of aberrant 
structures (119). However, a still unresolved issue, limiting the efficacy of both cell 
therapy and cell-based gene therapy approaches, is the poor engraftment of injected 
cells in the myocardium (122). 
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4 Aim of the thesis 
An adequate reperfusion of the infarcted tissue upon remains a formidable challenge 
in the management of MI. The concept of inducing angiogenesis for a therapeutic 
purpose aims at meeting this specific clinical need. Direct delivery of VEGF by a gene 
therapy approach has been for over 15 years the most investigated strategies and, 
although promising, presents still major limitations, due to the inefficiency of current 
transgene vectors in guaranteeing adequate and sustained expression levels of the 
VEGF triggering safe, mature and stable angiogenesis. In this context, optimizing ex 
vivo the VEGF transgene expression from a cell population suitable to be re-injected in 
vivo could offer a superior control over the genetic manipulation procedure. 
Nevertheless, this approach is still limited by major unsolved issues mostly related to 
the transplantation of the cell population in vivo. In particular, although still 
inadequate for the treatment of MI, direct epicardial or intracoronary injections still 
represent the standard methods for cell delivery in the myocardium. Beyond the poor 
cell engraftment that it has been observed in several independent studies, these 
delivery systems restrict the effect area to the injection site limiting the portion of the 
tissue that could receive benefits from the treatment. On the other hand, an epicardial 
delivery of a preformed tissue could cover homogeneously the affected area rather 
than having only scattered spots treated. In this context, the generation of proto-
engineered tissue (patch) in vitro could also favour the cell survival upon implantation, 
as observed in previous studies performed by our and other groups (123)(124). 
Therefore, in my PhD project I focused on the use of engineered tissues (patch) as 
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VEGF delivery system to trigger an efficient pro-angiogenic signal able to induce a safe 
and mature vasculature.  
In order to induce a safe vasculature and prevent the formation of aberrant structures 
caused by high doses of VEGF, it is crucial to control the expression of the protein at 
the microenvironmental level. As previously described, this can be achieved by 
controlling the VEGF expression of every single cell transplanted through a FACS based 
purification technique.  
Hence, the first part of the thesis aimed at generating the patch by seeding a 
population of ASC purified to express safe levels of VEGF on a type I collagen scaffold, 
and give the “proof of principle” of its efficiency in inducing extrinsic angiogenesis 
(CHAPTER II). 
  
VEGF164 interacts with Extracellular matrix proteins through its heparin-binding 
domain. Therefore, the microenvironmental concentration depends, at least in part, 
from the composition and the abundance of heparin enriched ECM proteins (as 
previously discussed in the section 2.2.1.2). In this context, a scaffold made of type I 
collagen that has no affinity for VEGF could modulate the concentration of the protein 
around the seeded cells, acting as a diffusion system. Based on the hypothesis that the 
biological composition of the scaffolds allows VEGF to diffuse, normalizing the 
deleterious effect uncontrolled VEGF overexpression, in the second part of the work 
we investigated the possibility to obtain a safe and functional patch by seeding not 
purified VEGF expressing ASC (CHAPTER III). 
  
36 
 
5 References 
1. World Health Organization. Media centre/fact sheet. Website World Health 
Organization. (Online) 2015. http://www.who.int/mediacentre/factsheets/fs317/en/. 
2. Pathophysiology of coronary artery disease. Libby P. and Theroux P. 2005, 
Circulation 111, 3481-3488. 
3. Atherosclerosis - An Inflammatory Disease. Ross R. 1999, New England Journal of 
Medicine 340,  115-126. 
4. Acute myocardial infarction. White H.D. and Chew D.P. 2008, Lancet 372, 570–584. 
5. Evidence for cardiomyocyte renewal in humans. Bergmann O., et al. 2009, Science 
324, 98-102. 
6. A role for pericytes in coronary no-reflow. O'Farrell F.M. and Attwell D.  2014, Nat. 
Rev. Cardiol. 11, 427-432. 
7. Myocardial no-reflow in humans. Niccoli G., et al. 2009, J. Am. Coll. Cardiol. 54, 281-
292. 
8. Heart failure. McMurray J.J. and Pfeffer M.A. 2005, Lancet 365, 1877-1889. 
9. Regeneration of the heart. Steinhauser M.L. and Lee R.T. 2011, EMBO Mol. Med. 3, 
701-712. 
10. Ventricular myocytes are not terminally differentiated in the adult mammalian 
heart. Anversa P. and Kajstura J. 1998, Circ. Res. 83, 1-14. 
11. Cardiovascular regenerative medicine: the developing heart meets adul heart 
repair. 2009, Circ. Res. 105, 1041-1043. 
12. Origin of cardiomyocytes in the adult heart. Leri A., et al. 2015, Circ. Res. 116, 150-
166. 
37 
 
13. Cell transplantation for myocardial repair: an experimental approach. Marelli D., et 
al. 1992 Cell Transplant., 1, 383-390. 
14. Myocyte renewal and ventricular remodelling. Anversa P. and Nadal-Ginard B. 
2002, Nature 415, 240-243. 
15. Bone marrow cells regenerate infarcted myocardium. Orlic D., et al. 2001, Nature 
410, 701-705. 
16. The winding road to regenerating the human heart. Gerbin K.A. and Murry C.E. 
2015, Cardiovasc. Pathol. 24, 133-140. 
17. The Effect of Bone Marrow Derived Mononuclear Cell Treatment, Early or Late After 
Acute Myocardial Infarction: Twelve Months CMR and Long-Term Clinical Results. 
Suerder D., et al. 2016, Circ. Res. (Epub ahead of print). 
18. One-year follow-up of intracoronary stem cell delivery on left ventricular function 
following ST-elevation myocardial infarction. Traverse J.H., et al. 2014, JAMA 311, 301-
302. 
19. Cell therapy for cardiac repair--lessons from clinical trials. Behfar A., et al. 2014, 
Nat. Rev. Cardiol. 3, 232-246. 
20. Paracrine mechanisms in adult stem cell signaling and therapy. Gnecchi M., et al. 
2008, Circ Res. 103, 1204-1219. 
21. Cardiac cell therapy: lessons from clinical trials. Menasche P. 2011, J. Mol. Cell. 
Cardiol. 50, 258-265. 
22. Bone-derived stem cells repair the heart after myocardial infarction through 
transdifferentiation and paracrine signaling mechanisms. Duran J.M., et al. 2013, Circ. 
Res. 113, 539-552. 
38 
 
23. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human 
primate hearts. Chong J.J., et al. 2014, Nature 510, 273-277. 
24. Cardiac repair in a porcine model of acute myocardial infarction with human 
induced pluripotent stem cell-derived cardiovascular cells. Ye L., et al. 2014, Cell Stem 
Cell 6, 750-761. 
25. Human embryonic stem cells vs human induced pluripotent stem cells for cardiac 
repair. Barad L., et al. 2014, Can. J. Cardiol., Vol. 30, pp. 1279-1287. 
26. Targeting angiogenesis to restore the microcirculation after reperfused MI. Van der 
Laan A.M., et al. 2009, Nat. Rev. Cardiol. 6, 515-523. 
27. Angiogenesis in wound healing. Tonnesen M.G.,et al. 2000, J. Investig. Dermatol. 
Symp. Proc. 5, 40-46. 
28. Therapeutic angiogenesis for critical limb ischaemia. Annex B.H. 2013, Nat. Rev. 
Cardiol. 10, 387-396. 
29. The number and distribution of capillaries in muscles with calculations of the 
oxygen pressure head necessary for supplying the tissue. Krogh, A. 1919, J. Physiol. 52, 
409–415. 
30. Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. 
Krogh's model. Chow D.C., et al. 2001, Biophys J. 81, 675-684. 
31. Abnormal blood vessel development and lethality in embryos lacking a single VEGF 
allele. Carmeliet P., et al. 1996, Nature 380, 435-439. 
32. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. 
Shalaby F., et al. 1995, Nature 376, 62-66. 
39 
 
33. A common progenitor for haematopoietic and endothelial lineages in the zebrafish 
gastrula. Vogeli K.M., et al. 2006, Nature 443, 337-339. 
34. Endothelial cells and VEGF in vascular development. Coultas L., et al. 2005, Nature 
438, 937-945. 
35. Molecular regulation of vessel maturation. Jain R.K. 2003, Nat. Med. 9, 685-693. 
36. Developmental and pathological angiogenesis. Chung A.S. and Ferrara N. 2011, 
Annu. Rev. Cell. Dev. Biol. 27, 563-584. 
37. Flow regulates arterial-venous differentiation in the chick embryo yolk sac. Le 
Noble F., et al. 2004, Development 131, 361-375. 
38. Gridlock signalling pathway fashions the first embryonic artery. Zhong, T.P., et al. 
2001, Nature 414, 216-220. 
39. Molecular distinction and angiogenic interaction between embryonic arteries and 
veins revealed by ephrin-B2 and its receptor Eph-B4. Wang H.U. et al. 1998, Cell 93, 
741-753. 
40. Segregation of arterial and venous markers in subpopulations of blood islands 
before vessel formation. Herzog Y., et al. 2005, Dev. Dyn. 232, 1047-1055. 
41. Morphological and molecular aspects of physiological vascular morphogenesis. 
Ribatti D., et al. 2009, Angiogenesis 12, 101-111. 
42. Angiogenesis in life, disease and medicine. Carmeliet P. 2005, Nature 438, 932-936. 
43. Vascular-specific growth factors and blood vessel formation. Yancopoulos G.D., et 
al.  2000, Nature 407, 242-248. 
44. Tumor cells secrete a vascular permeability factor that promotes accumulation of 
ascites fluid. Senger D.R., et al. 1983, Science 219, 983-985. 
40 
 
45. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for 
vascular endothelial cells. Ferrara N. and Henzel W.J. 1989, Biochem. Biophys. Res. 
Commun. 161, 851-858. 
46. VEGF-B is dispensable for blood vessel growth but critical for their survival, and 
VEGF-B targeting inhibits pathological angiogenesis. Zhang F., et al. 2009, Proc. Natl. 
Acad. Sci. U S A 106, 6152-6157. 
47. Vascular endothelial growth factor C is required for sprouting of the first lymphatic 
vessels from embryonic veins. Karkkainen M.J., et al. 2004, Nat. Immunol. 5, 74-80. 
48. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network 
formation. Tammela T., et al. 2008, Nature 454, 656–660. 
49. Placental growth factor promotes atherosclerotic intimal thickening and 
macrophage accumulation. Khurana R., et al. 2005, Circulation 111, 2828–2836. 
50. Common mechanisms of nerve and blood vessel wiring. Carmeliet P. and Tessier-
Lavigne M. 2005, Nature 436, 193-200. 
51. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific 
receptor for vascular endothelial growth factor. Soker S., et al. 1998, Cell 92, 735-745. 
52. Corneal avascularity is due to soluble VEGF receptor-1. Ambati B.K., et al. 2006, 
Nature 443, 993–997. 
53. Proteolytic processing regulates receptor specificity and activity of VEGF-C. Joukov 
V., et al. 1997, EMBO J. 16, 3898-3911. 
54. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Lohela 
M., et al. 2009, Curr Opin Cell Biol. 21, 154-165. 
41 
 
55. Vascular endothelial growth factor: basic science and clinical progress. Ferrara, N. 
2004, Endocr. Rev. 25, 581-611. 
56. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated 
by splicing and growth factors. Nowak D.G., et al. 2008, J. Cell Sci. 121, 3487-3495. 
57. Dual regulation of vascular endothelial growth factor bioavailability by genetic and 
proteolytic mechanisms. Houck K.A., et al. 1992, J. Biol. Chem. 267, 26031-26037. 
58. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. 
Vempati P., et al. 2014, Cyt. Gro.Fac. Rev., Vol. 25, pp. 1-19. 
59. Binding to the extracellular matrix and proteolytic processing: two key mechanisms 
regulating vascular endothelial growth factor action. Ferrara N. 2010, Mol. Biol. Cell. 
21, 687-690. 
60. Spatially restricted patterning cues provided by heparin-binding VEGF-A control 
blood vessel branching morphogenesis. Ruhrberg C., et al. 2002, Genes Dev., 16, 2684-
2698. 
61. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF 
isoforms. Stalmans I., et al. 2002, J. Clin. Invest., 109, 327-336. 
62. Molecular mechanisms and clinical applications of angiogenesis. Carmeliet P. and 
Jain R.K. 2011, Nature 473,298-307. 
63. Autocrine VEGF signaling is required for vascular homeostasis. Lee S., et al. 2007, 
Cell 130, 691-703. 
64. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie 
system. Augustin H.G., et al. 2009, Nat. Rev. Mol. Cell. Biol. 10, 165-177. 
42 
 
65. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. Gerhardt, 
H., et al. 2003, J. Cell Biol. 161, 1163-1177. 
66. The extracellular matrix of blood vessels. Eble J.A. and Niland S. 2009, Curr. Pharm. 
Des. 15, 1385-1400. 
67. Extracellular matrix, inflammation, and the angiogenic response. Arroyo A.G. and 
Iruela-Arispe M.L. 2010, Cardiovasc. Res. 86, 226-235. 
68. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. 
Benedito R., et al. 2009, Cell 137, 1124–1135. 
69. VEGF and Notch in tip and stalk cell selection. Blanco R. and Gerhardt H. 2013, Cold 
Spring Harb. Perspect. Med. 3, 1-19. 
70. Basic and therapeutic aspects of angiogenesis. Potente M., et al. 2011, Cell 146, 
873-887. 
71. Escape mechanisms after antiangiogenic treatment, or why are the tumors growing 
again? Hlushchuk R., et al. 2011, Int. J. Dev. Biol. 55, 563-567. 
72. Intussusceptive angiogenesis: its role in embryonic vascular network formation. 
Djonov V., et al. 2000, Circ. Res. 86, 286-292. 
73. VEGF over-expression in skeletal muscle induces angiogenesis by intussusception 
rather than sprouting. Gianni-Barrera R., et al. 2013, Angiogenesis 16, 123-136. 
74. Blood flow shapes intravascular pillar geometry in the chick chorioallantoic 
membrane. Lee G.S., et al. 2010, J. Angiogenes. Res. 2. 
75. Mechanisms of Vessel Pruning and Regression. Korn C. and Augustin, H.G. 2015, 
Dev. Cell 34, 5-17. 
43 
 
76. Brothers and sisters: molecular insights into arterial-venous heterogeneity. 
Aitsebaomo J., et al. 2008, Circ. Res. 103, 929-939. 
77. Molecular regulation of vessel maturation. Jain R.K. 2003, Nat Med. 9, 685-93. 
78. Role of platelet-derived growth factors in physiology and medicine. Andrae J., et al. 
2008, Genes Dev. 22 , 1276-312. 
79. Signaling by members of the TGF-beta family in vascular morphogenesis and 
disease. Pardali E., et al. 2010, Trends Cell Biol. 20, 556-567. 
80. Eph/ephrin molecules--a hub for signaling and endocytosis. Pitulescu M.E., et al. 
2010, Genes Dev. 24, 2480-2492. 
81. VEGF-induced adult neovascularization: recruitment, retention, and role of 
accessory cells. Grunewald M., et al. 2006, Cell 124, 175-189. 
82. VEGF-A and PDGF-B combination gene therapy prolongs angiogenic effects via 
recruitment of interstitial mononuclear cells and paracrine effects rather than 
improved pericyte coverage of angiogenic vessels. Korpisalo P., et al. 2008, Circ. Res. 
103, 1092-1099. 
83. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial 
formation at the sites of adult neoangiogenesis in mice. Zacchigna S., et al. 2008, J. 
Clin. Invest. 118, 2062-2075. 
84. Neuropilin-1 identifies a subset of bone marrow Gr1- monocytes that can induce 
tumor vessel normalization and inhibit tumor growth. Carrer A., et al. 2012, Cancer 
Res. 72, 6371-6381. 
44 
 
85. VEGF dose regulates vascular stabilization through Semaphorin3A and the 
Neuropilin-1+ monocyte/TGF-β1 paracrine axis. Groppa E., et al. 2015, EMBO Mol. 
Med. 7, 1366-1384. 
86. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in 
patient with ischaemic limb. Isner J.M., et al. 1996, Lancet 348, 370-374. 
87. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes 
collateral vessel development in patients with critical limb ischemia. Baumgartner I., et 
al. 1998, Circulation 97, 1114-1123. 
88. Gene therapy for myocardial angiogenesis: initial clinical results with direct 
myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Losordo 
D.W., et al. 1998, Circulation 98, 2800-2804. 
89. The stimulation of neoangiogenesis in the ischemic human heart by the growth 
factor FGF: first clinical results. Schumacher B., et al. 1998, J. Cardiovasc. Surg. (Torino) 
39, 783-789. 
90. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular 
Angiogenesis. Henry T.D., et al. 2003, Circulation 107, 1359-1365. 
91. VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Giacca M. e 
Zacchigna S. 2012, Gene Ther. 19, 622-629. 
92. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene 
therapy in patients with stable severe angina pectoris A randomized double-blind 
placebo-controlled study: the Euroinject One trial. Kastrup, J., et al. 2005, J. Am. Coll. 
Cardiol. 45, 982-988. 
45 
 
93. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients 
with advanced coronary disease: results of the NORTHERN trial. Stewart D.J., et al. 
2009, Mol. Ther. 17, 1109-1115. 
94. Conditional switching of VEGF provides new insights into adult neovascularization 
and pro-angiogenic therapy. Dor Y., et al. 2002, EMBO J. 21, 1939-1947. 
95. Safety and feasibility of catheter-based local intracoronary vascular endothelial 
growth factor gene transfer in the prevention of postangioplasty and in-stent 
restenosis and in the treatment of chronic myocardial ischemia: phase II results of the 
KAT. Hedman M., et al. 2003, Circulation 107, 2677-2683. 
96. Therapeutic angiogenesis for myocardial ischemia revisited: basic biological 
concepts and focus on latest clinical trials. Gilgenkrantz H., et al. 2012, Angiogenesis 
15, 1–22. 
97. Cardiovascular gene therapy for myocardial infarction. Scimia, M.C., et al. 2014, 
Expert Opin. Biol. Ther. 14, 183-195. 
98. Current gene therapy trials for vascular diseases. Halonen P.J., et al. 2014, Expert 
Opin. Biol. Ther. 14, 327-336. 
99. Evaluation of the effects of intramyocardial injection of DNA expressing vascular 
endothelial growth factor (VEGF) in a myocardial infarction model in the rat--
angiogenesis and angioma formation. Schwarz E.R., et al. 2000, J. Am. Coll. Cardiol. 35, 
1323–1330. 
100. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. 
Lee, R.J., et al. 2000, Circulation, Vol. 102, p. 898–901. 
46 
 
101. Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in 
skeletal muscle. Karvinen H., et al. 2011, Gene Ther. 18, 1166-1172. 
102. Microenvironmental VEGF concentration, not total dose, determines a threshold 
between normal and aberrant angiogenesis. Ozawa C.R., et al. 2004, J. Clin. Invest. 
113,  516–527. 
103. Heterogeneity of the angiogenic response induced in different normal adult tissues 
by vascular permeability factor/vascular endothelial growth factor. Pettersson A., et 
al. 2000, Lab Invest. 80, 99–115. 
104. Critical role of microenvironmental factors in angiogenesis. Banfi A., et al. 2005, 
Curr. Atheroscler. Rep. 7, 227-234. 
105. Regulation of an endogenous locus using a panel of designed zinc finger proteins 
targeted to accessible chromatin regions. Activation of vascular endothelial growth 
factor A. Liu P.Q., et al. 2001, J. Biol. Chem. 276, 11323-11334. 
106. Vascular endothelial growth factor-delivery systems for cardiac repair: an 
overview. Simón-Yarza T., et al. 2012, Theranostics, 2, 541-552. 
107. Hydrogels for therapeutic cardiovascular angiogenesis. Rufaihah A.J. and Seliktar 
D. 2016, Adv. Drug. Deliv. Rev. 96, 31-39. 
108. Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly 
tunable, sustained delivery of recombinant VEGF164. Sacchi V., et al. 2014, Proc. Natl. 
Acad. Sci. U S A 111, 6952-6957. 
109. The host response to allogeneic and xenogeneic biological scaffold materials. 
Keane T.J.  Badylak S.F. 2015, J. Tissue Eng. Regen. Med. 9, 504-511. 
110. Gene therapy returns to centre stage. Naldini L. 2015, Nature, 526, 351–360. 
47 
 
111. Vascular Regeneration in Ischemic Hindlimb by Adeno-Associated Virus Expressing 
Conditionally Silenced Vascular Endothelial Growth Factor. Boden J., et al. 2016, J. Am. 
Heart Assoc. 5. 
112. Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis. 
von Degenfeld G., et al. 2003, Br. J. Pharmacol. 140, 620-626. 
113. Cell transplantation for the treatment of acute myocardial infarction using 
vascular endothelial growth factor-expressing skeletal myoblasts. Suzuki K., et al., 
2001, Circulation 104, 207-212. 
114. Baculovirus-transduced, VEGF-expressing adipose-derived stem cell sheet for the 
treatment of myocardium infarction. Yeh T.S., et al., 2014, Biomaterials 35, 174-184. 
115. Transplantation of modified human adipose derived stromal cells expressing 
VEGF165 results in more efficient angiogenic response in ischemic skeletal muscle. 
Shevchenko E.K., et al. 2013, J. Transl. Med. 6, 138. 
116. Generation of human adult mesenchymal stromal/stem cells expressing defined 
xenogenic vascular endothelial growth factor levels by optimized transduction and flow 
cytometry purification. Helmrich U., et al. 2012, Tissue Eng. Part C Methods. 18, 283-
292. 
117. Vascular endothelial growth factor-expressing mesenchymal stem cell 
transplantation for the treatment of acute myocardial infarction. Matsumoto R., et al. 
2005, Arterioscler. Thromb. Vasc. Biol. 25, 1168-1173. 
118. Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies. 
D'souza N., et al. 2015, BMC Med. 13. 
48 
 
119. Controlled angiogenesis in the heart by cell-based expression of specific vascular 
endothelial growth factor levels. Melly L.F., et al. 2012, Hum. Gene Ther. Methods. 23, 
346-356. 
120. High-throughput flow cytometry purification of transduced progenitors expressing 
defined levels of vascular endothelial growth factor induces controlled angiogenesis in 
vivo. Misteli H., et al. 2010, Stem Cells 28, 611–619. 
121. FACS-purified myoblasts producing controlled VEGF levels induce safe and stable 
angiogenesis in chronic hind limb ischemia. Wolff T., et al. 2012, J. Cell. Mol. Med. 16, 
107–117. 
122. Cell and gene therapy approaches for cardiac vascularization. Melly L., et al. 2012, 
Cells 1, 961–975. 
123. Improving cell engraftment with tissue engineering. Suuronen E.J., et al. 2008, 
Semin. Thorac. Cardiovasc. Surg. 20, 110-114. 
124. How to Improve the Survival of Transplanted Mesenchymal Stem Cell in Ischemic 
Heart? Liangpeng L., et al. Stem Cells Int. 22, 9682757. 
  
49 
 
 
 
 
 
 
Chapter II: Engineered mesenchymal cell-based patches 
as controlled VEGF delivery systems to induce extrinsic 
angiogenesis 
The data presented in this chapter have been published in Acta Biomaterialia, doi: 
10.1016/j.actbio.2016.07.041 
  
50 
 
1 Introduction 
 Promising pro-angiogenic strategies based on the delivery of potent angiogenic 
factors, as the vascular endothelial growth factor-A (VEGF), have been investigated to 
induce growth of blood vessels in ischemic tissues (1) (2). Rapid and efficient 
restoration of the microvasculature is particularly crucial and challenging after a 
myocardial infarction to rescue organ function (3). Phase I and II clinical studies based 
on VEGF gene therapy showed inconsistent outcomes in cardiac functionality in 
patients after myocardial infarction, likely due to the low local transfection efficacy, 
resulting in limited amount and duration of the protein expression (4)(5). In fact, VEGF 
expression needs to be controlled within a defined therapeutic window (6) and 
sustained for a period of at least four weeks to allow the maturation and the 
stabilization of the newly formed blood vessels (7). Control over the dose and timing of 
VEGF release could be achieved by functionalized biomaterials (8) (9) (10) though with 
some shortcomings with regard to the limited factor supply and the unforeseeable 
potency of the local host immune reaction (11). A cell-based gene therapy approach 
could overcome such limitations by inducing a suitable cell population to overexpress 
the specific angiogenic gene (12). However, the microenvironmental dose of VEGF 
needs to be controlled in order to avoid the growth of aberrant vascular structures and 
angioma-like tumors, which would jeopardize clinical benefit (13) (14). In order to 
ensure controlled expression of homogeneous VEGF levels in vivo, we recently 
developed a high-throughput FACS-based technology to rapidly purify populations of 
transduced human adipose-derived mesenchymal stromal cells (ASC) that produce 
only specific desired VEGF levels (15) (16). However, another key issue that severely 
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limits the therapeutic efficacy of this approach is the poor survival of delivered ASC 
after direct intra-myocardial injection (17) (18) (19). The global treatment of all 
affected areas is also difficult by cell injections. Delivery of cells following in vitro 
organization into engineered constructs may provide superior control over the 
targeted cardiac segments and enhance the implanted cell survival, thereby sustaining 
the delivery of the therapeutic signals (20) (21). Therefore, in this study as proof of 
principle we aim to combine a purified population of genetically modified ASC and a 
scaffold-based engineered patch to provide both spatial and dose control in VEGF 
delivery. Although three major splicing isoforms of VEGF exist (comprised of 120/121, 
164/165, and 188/189 amino acids in rodents and humans, respectively) (22), in this 
study we focused on VEGF164 because it is the only isoform able to induce a 
physiologically patterned vasculature as a single factor in the absence of the others 
(23). 
During in vitro 3D culture, bioreactors for direct perfusion of the medium were used to 
promote the reproducibility and the quality of cell-based patches by uniform 
distribution during seeding and efficient provision of nutrients and oxygen in mm-thick 
porous collagen scaffolds (24). In particular, we hypothesized that FACS-purified VEGF-
expressing ASC pre-cultured in perfusion bioreactors on 3D sponges can provide a 
controlled and sustained VEGF release to induce safe and efficient angiogenesis both 
within the engineered patch (intrinsic) and in a surrounding area of clinically relevant 
size (extrinsic). Since the extrinsic angiogenic potential of the engineered tissues was 
assessed in a subcutaneous mouse model, we used a several mm-thick cell-free 
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collagen scaffold (empty) to provide a standardized and controlled region in which to 
investigate dynamics of vascular growth. 
2 Materials and methods 
2.1 Cell transduction and sorting 
Adipose tissue was obtained from a healthy donor undergoing plastic surgery after 
informed consent and according to a protocol approved by the Ethical Committee of 
Basel University Hospital. All investigations conform to the Declaration of Helsinki. 
Tissue was minced and digested with 0.15% collagenase (Worthington Biochemical 
Corporation, Lakewood, NJ) in PBS at 37 °C under continuous shaking for 60 minutes. 
Released cells were strained through a 70 µm nylon mesh, plated at a density of 105 
cells/cm2 and cultured in high-glucose DMEM medium with 10% FBS. After 4 days, 
cells were transduced with retroviral vectors expressing rat VEGF164, linked in a 
bicistronic expression cassette to a truncated version of rat CD8a as a convenient 
FACS-sortable surface marker, as previously described (15). After 12 days, transduced 
ASC at p0 were FACS-sorted with a BD Influx Cell Sorter (BD Biosciences, Basel, 
Switzerland) with a gate determined by a reference clonal population of murine 
skeletal myoblasts expressing safe and specific VEGF levels (16). Two different cell 
groups were generated: (i) naïve ASC as control and (ii) cells expressing a specific safe 
VEGF level (VEGF-ASC). 
2.2 Patch preparation and in vivo implantation 
Engineered constructs (patches) were generated using either I) naïve ASC or II) VEGF-
ASC. Bovine type I collagen scaffold (Ultrafoam™, Bard; size: 12mm diameter 3 mm 
thickness) were placed in the bioreactor chamber as previously described (25). Briefly, 
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ASC (2.2x106 cells/construct) were seeded and cultured throughout the inner 8 mm of 
the scaffold by a perfusion-based system at a speed of 3 ml/min for the first 18 hours 
and at 0.15 ml/min for the subsequent 5 days. Patches were then removed from the 
bioreactor, cut with 8mm punch to remove the not perfused rim of collagen and 
stitched with 2 points of surgical suture to a 8mm diameter and 7 mm thick empty 
scaffold (empty scaffold).  
Animals were treated in compliance with Swiss Federal guidelines for animal welfare 
and all procedures were approved by the Veterinary Office of the Canton Bern (Bern, 
Switzerland) and conform to the Directive 2010/63/EU of the European Parliament. 
Male nude mice (Hsd: RH-rnu/rnu) were anesthetized by inhalation using a mixture of 
oxygen (0.6 L/min) and Isoflurane (1.5–3 vol%). Grafts were implanted in subcutaneous 
pockets in the back of the mouse. After 7, 14 and 28 days post-implantation, mice 
were anesthetized by intraperitoneal injection of a mixture of Ketamine (100 mg/Kg) 
and Xylazin (10 mg/Kg) prior sacrifice by total body vascular perfusion of 1% 
paraformaldehyde (PFA). The harvested constructs were further fixed in PFA 4% for 5 
hours and left in 30% sucrose in PBS overnight, before embedding in OCT compound 
(Sakura Finetek, Torrance, CA) and freezing in liquid nitrogen-cooled isopentane 
vapors. 
2.3 DNA assay 
For  DNA assay, patches (n=3) were collected from bioreactors, washed twice in PBS 
and digested overnight at 56 °C with protease K (0.5 mL of 1 mg/mL protease K in 50 
mM Tris with 1 mM EDTA, 1 mM iodoacetamide, and 10 mg/mL pepstatin-A). Total 
DNA amount was measured with the CyQUANT® Cell Proliferation Assay Kit (Life 
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Technologies). DNA concentration was determined by reading the absorbance value at 
485 nm using a Sinergy H1 Hybrid Reader (Biotek instruments Gmbh, Lucern, 
Switzerland).  
2.4 Flow cytometer analysis 
For phenotypic characterization of 3D-cultured VEGF-ASC, patches (n=3 per condition) 
were digested in 0.15% collagenase (Worthington Biochemical Corporation, Lakewood, 
NJ), liberated cells were collected by centrifugation and incubated for 20 min on ice, in 
PBS with 5% bovine serum albumin (BSA). The antibodies used were: CD90-FITC, CD73-
PE, CD31-FITC, CD45-FITC, IgG1-FITC, IgG1-PE, IgG-APC (all from Becton and Dickinson 
Company, Franklin Lakes, NJ), CD105-FITC (Serotec Ltd. Oxford, UK), and VEGF-R2-FITC 
(R&D Systems). All the antibodies were used at a dilution of 1:50, except CD105-FITC, 
which was used at 1:20. Data were acquired with a FACSCalibur flow cytometer (BD 
Biosciences). For cell cycle analysis cells, retrieved from the patch, were fixed in 70% 
ethanol and incubated in a solution containing propidium iodide (Sigma-Aldrich) 10 
µg/ml in PBS and RNAase 10 µg/ml for 20 minutes at 37 °C. Data were acquired with 
Fortessa II cytometer (BD Biosciences) and analysed by using FlowJo software (Tree 
Star, Ashland, OR, USA). 
2.5 MTT staining 
Qualitative spatial distribution of living cells was assessed by MTT (3(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich) staining. Active 
mitochondria convert this tetrazolium salt into an insoluble formazan which stains cells 
purple.  Samples were cut in half, rinsed in PBS and incubated at 37 °C for 2 hours with 
3 ml of 0.12 mM MTT. 
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2.6 Histology 
All histological analyses were performed on frozen sections. For basic 
histomorphological evaluation, sections were stained with hematoxylin and eosin 
(H&E) according to standard protocols. Color images were acquired with an Olympus 
BX63 microscope (Olympus, Volketswil, Switzerland) or a Zeiss LSM710 confocal 
microscope (Zeiss, Oberkochen, Germany). For immunofluorescence analyses 
cryosections were incubated for 1 hour in 0.3% Triton X-100 and 2% normal goat 
serum in PBS, and then for 1 hour in the following primary antibodies and dilutions: (1) 
anti-CD31 (AbDSerotec, Düsseldorf, Germany) at 1:100, (2) anti-NG2 (Millipore, Zug, 
Switzerland) at 1:200, (3) anti-α Smooth-Muscle Actin (Sigma-Aldrich, Basel, 
Switzerland) at 1:400, (4) anti-cleaved Caspase-3 (Asp175) (Cell Signaling Technology, 
Allschwil, Switzerland) at 1:100, (5) anti-Ki-67 (AbCam, Cambridge, UK) at 1:200, (6) 
anti-Human Nuclei clone 235-1 (Millipore, Billerica, MA, USA) at 1:100, anti-laminin 
(AbCam, Cambridge, UK) at 1:400, anti-VE-Cadherin (Santa Cruz  Biotechnology Dallas, 
Texas,  USA) at 1:200 . All secondary antibodies were used at 1:200 for 1 hour 
incubation (Life Technologies, Basel, Switzerland). Nuclei were stained using DAPI 
(Invitrogen, Switzerland). All antibodies were diluted in 0.3% Triton X-100 and 2% 
normal goat serum in PBS. 
 2.7 Vessel length density quantification 
The amount of blood vessels was quantified on images taken from CD31-stained 
sections by determining the total vessel length density (VLD). Six representative 
fluorescent images per sample (4 samples per group) were acquired with a 20x 
objective on an Olympus BX61 microscope (Olympus, Münster, Germany), both in the 
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patch and in the empty scaffold areas (at the center and at the border). The total 
length of the capillaries was measured by tracing the CD31-positive vessels using 
CellSens software (Soft Imaging System, Münster, Germany). The vessel length density 
was then determined by dividing the total vessel length by the area of each field.  
2.8 Human cell quantification 
Human cell survival was evaluated by assessing the human cell density at 28 days post 
implantation. Six representative fluorescent images per sample (2 samples per group; 
n=12) were acquired both in the patch and in the area of the empty scaffold below the 
patch (100 µm away from the border with the patch) with 20x magnification on an 
Olympus BX63 microscope (Olympus, Volketswil, Switzerland) on cross-sections. Cells 
positive for human nuclei staining (see paragraph 2.6) were counted using ImageJ 1.47 
software (Research Service Branch, NIH, USA) and divided by the image area to obtain 
the cell density. The in vivo percentage of proliferating ASC at 28 days was assessed by 
dividing the number of double positive Human Nuclei (HuNu) and Ki-67 cells by the 
total amount of human cells. 
2.9 Elisa assay  
The rate of VEGF production by ASC was quantified in the supernatant of 2D cell 
culture using a Quantikine rat VEGF immunoassay enzyme-linked immunosorbent 
assay (ELISA) kit (R&D Systems), as previously described (16). Briefly, 4 milliliters of 
fresh medium was added on Naïve or VEGF-ASCs cultured in 60-mm dishes in 
quadruplicate for 4h, collected, filtered, and frozen. Results were normalized by the 
number of cells in each dish and the time of incubation and expressed as ng/106 
cells/day. For the estimation of VEGF concentrations in the patches during 3D culture, 
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patches were removed from the bioreactor after 4 days and immediately frozen. After 
homogenization of the patch in a PBS+1% Triton X-100 buffer, VEGF concentration was 
assessed with an ELISA kit (R&D Systems) and values were normalized by the 
estimated number of cells (according to the average of cell seeding efficiency) and the 
amount of the medium present in the bioreactor and expressed as ng/106 cells. 
2.10 Statistics 
Data were analyzed with the statistical software Prism 4.0a (GraphPad, La Jolla, CA) 
and SPSS 17.0 (IBM, Armonk, NY). Data are presented as means ± standard deviation. 
Comparison between groups was performed using a one-way ANOVA with Bonferroni 
correction for the VEGF quantification and a mixed-effects model for the angiogenesis 
quantification. P<0.05 was considered statistically significant. 
3. Results 
3.1 Engineered tissue characterization 
Direct perfusion of culture medium through the scaffold allowed a uniform cell 
distribution through the entire thickness (top, center and bottom) of the collagen 
sponge (Fig 1A). Quantification of the nuclei by image analysis confirmed the 
homogeneous cell distribution (about 300-350 cells/mm2) throughout the entire 
construct cross-section (Fig. 1B). Seeding efficiency was measured by quantifying the 
amount of genomic DNA of the total amount of cells used for the seeding (as 
reference) and that retrieved from the scaffold 1 day after the loading and after 
further 5 days of perfusion culture (Fig 1C). The seeding efficiency was very high 
(98.3%±0.5% after 1 day compared with the reference amount of DNA). Macroscopic 
images of patches stained for metabolically active cells by using MTT excluded the 
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presence of a necrotic central core (Fig. 1 D), further confirming the homogeneous cell 
viability in the scaffold after 5 days of culture. 
 
Fig 1 Characterization of the ASC-based patches. A) Representative pictures of hematoxylin and eosin 
staining taken at top, middle and bottom part of the scaffold (from the left to the right, respectively) 
(size bar=100 µm). B) Quantification of cell density distribution by image analysis of 9 random fields per 
sample (n=3 samples/condition). C) DNA amount Quantification of genomic DNA in the amount of cells 
used for the seeding (ref. after seeding) and present in constructs after 1 and 5 days of culture (n=3). D) 
Representative pictures of MTT staining on the entire scaffold after 5 days of culture (top and cross-
section view at low and high magnification: from the left to the right; scale bar=1mm). Graphs are 
showed as mean ± Standard Deviation (SD). 
 
3.2 Effect of VEGF expression on ASC 
VEGF164 is a potent mitogen and affects cell survival, with effects being conserved 
across species. Therefore, we investigated its possible effects on human ASC 
proliferation, apoptosis and phenotype. No significant difference was found in the cell 
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density after 5 days of culture in constructs generated by VEGF-expressing and naïve 
ASC (Fig. 2A). Furthermore, cell cycle analysis with propidium iodide by cytofluorimetry 
showed that the majority of the cells (about 80%) was in G0/G1 phase in both 
experimental groups (Fig. 2B-C), thus confirming that VEGF expression did not increase 
ASC proliferation. Low doubling rates for both naïve and VEGF-ASC were also 
confirmed by immunofluorescence staining for Ki-67 protein, a marker expressed in 
actively proliferating cells in all phases of the cell cycle (Fig. 2D). VEGF expression by 
ASC appeared also not to affect cell apoptosis, since no relevant differences were 
found in the expression of caspase 3 (CAS-3), a key-protein in the apoptotic process 
(Fig. 2E). Cytofluorimetry analyses for hematopoietic (CD45+) mesenchymal (CD73+, 
CD90+) and endothelial (CD31+, VEGFR-2+) markers showed, as expected, that the 
near-totality of the ASC were of mesenchymal/stromal origin, with no hematopoietic 
cells and a minor amount of endothelium. Importantly, no relevant changes in the ASC 
population composition occurred when VEGF was expressed (Fig. 2F). Monolayer-
expanded transduced ASC produced 58.5 ±11 ng/106 cells/day of rat VEGF (Fig. 2G), 
corresponding to the levels previously found to be safe and efficacious (16). Patches 
generated with ASC were then sutured on the top of empty collagen scaffold of critical 
size in order to assess their in vivo intrinsic and extrinsic angiogenic potential (Fig. 2H).  
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Fig 2 VEGF effects on ASC proliferation and phenotype in 3D in vitro culture.  A) Quantification of cell 
density in VEGF and Naïve patches after 5 days of dynamic culture (image analysis performed on 6 
random fields per sample; n=3 samples/condition). B) Representative histogram for flow cytometric 
analysis of cell cycle with propidium iodide emission for naïve (left) and VEGF- (right) ASC cultured on 3D 
collagen scaffold for 5 days. C) Quantification of percentage of cells present in either G0/G1 or S or 
G2/M cell cycle phase based on the flow cytometer analysis (n=3 per condition). D,E) 
Immunofluorescence staining for ki-67 and Cleaved Caspase-3 (green)  and cell nuclei (blue) in the 
patches after 5 days in perfusion bioreactors (size bar=20 µm and 100 µm respectively). F) Phenotypic 
characterization of VEGF and naïve ASC by flow cytometry analysis for hematopoietic (CD45), 
mesenchymal (CD90, CD73) and endothelial (CD31, VEGFR-2) markers. G) Quantification of the amount 
of rat VEGF released by transduced cells either in monolayer or in 3D perfusion-based culture. Data are 
presented as mean ± SD (n=4). H). Macroscopic view of the composed construct before implantation: 
the dashed black line distinguishes between the cell-based patch (patch) and the underneath cell-free 
collagen sponge (empty scaffold). At the border in blue there are the two surgical sutures (size bar= 5 
mm).  
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3.3 In vivo vascularization of the patch 
Before implantation, the amount of VEGF produced by transduced ASC after 3D 
perfusion culture was measured and was comparable to the rate of production 
measured during monolayer culture (41.9 ± 7.1 ng/106 cells). Upon implantation of 
mm-thick 3D patches, a prompt vascularization of the cell-seeded construct is essential 
to guarantee enough oxygen and nutrient provision to avoid cell loss. Moreover, in the 
scenario of angiogenesis induction through cell-based gene therapy, efficient survival 
of implanted cells is also crucial to achieve a sustained VEGF release. To investigate the 
kinetics of patch vascularization, we implanted cell-seeded patches ectopically in a 
subcutaneous pocket in nude mice and the resulting vascularization was analyzed at 
different time points (4, 14 and 28 days) by staining for the endothelial marker CD31. 
Vessel ingrowth was observed already after 4 days in VEGF-expressing patches and 
increased at 14 and 28 days in vivo (Fig. 3A-B). Branching points (white arrows in Fig. 
3A), that indicate the formation of a well inter-connected and physiological 
microvascular network, were observed almost exclusively in VEGF-expressing patches 
and increased with time in vivo (Fig. 3A). Naïve ASC constructs contained few 
endothelial cells in the center and only few vessels were observed even at late time 
points (Fig 3A). The vessel length density (VLD) was statistically significantly greater at 
all time points in VEGF patches (Fig. 2B). Endothelial structure density in naïve cell-
based constructs was similar at all time points. After 4 days in vivo, the vessel length 
density was 6-fold higher in the VEGF-ASC compared to control cell. A remarkable 4.9 
fold increase in VLD was observed at 14 days and was maintained up to 28 days in the 
VEGF-ASC patches compared to the naive. In VEGF-releasing patches, the newly 
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formed blood vessels were also tightly surrounded by pericytes, as shown by 
immunofluorescence staining for NG2, confirming the formation of mature capillaries 
(Fig. 3C-D). Further, only morphologically normal capillary networks were observed 
and no instances of enlarged, aberrant angioma-like vascular structures could be 
detected. Taken together, these results indicate that patches seeded with transduced 
and purified ASC expressing controlled VEGF levels support the intrinsic induction of 
safe, efficient and mature angiogenesis. 
 
Fig 3 Fig. 3 In vivo vascularization of the ASC-based patches. A) Representative images of blood vessel 
density in patches seeded with naïve and VEGF-ASC after 4 and 28 days in vivo, assessed by 
immunofluorescence for CD31 (red) (size bar=20 µm). B) Quantification of vessel length density (VLD) in 
the Naïve and VEGF patches at 4, 14 and 28 days upon implantation (image analysis performed on 6 
random fields per samples n= 4 samples/condition; **p<0.01; ***p<0.001. C, D) Representative images 
of newly formed blood vessels stained for maturation markers at 28 days in VEGF-ASC patch al low (C) 
and high (D) magnification. Immunofluorescence staining for cell nuclei (DAPI; Blu), endothelial cells 
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(CD31; red), pericyte (NG2; green) and smooth muscle cells (SMA, cyan); (size bars=100 µm (C) and 20 
µm (D)). 
3.4 Angiogenesis induction outside the patch 
To investigate the extrinsic pro-angiogenic potential of the engineered patches, the 
induction of vessel ingrowth was investigated in an empty collagen scaffold sutured 
underneath the cell-seeded patch and with a critical thickness of 7 mm. Host blood 
vessels reached the center of the empty scaffold only when VEGF-expressing cells were 
seeded in the patch sutured on top (Fig. 4A). In fact, at 28 days almost no vessels were 
present both in the center and at the border of the empty collagen scaffolds 
underneath the naïve ASC-based patches (Fig. 4A). At 4 days no host blood vessels 
reached yet the center of the acellular scaffold in both conditions (Fig 4A) and a 
negligible amount of sprouting capillaries was observed in the control sponge at later 
time points in vivo (Fig. 4A-B). On the contrary, VEGF-expressing patches induced a 
significant ingrowth of capillaries in the center of the underlying empty scaffold 
already by 14 days, which was maintained at 28 days (Fig. 4A-B, center). Host vessels 
start infiltrating the border of the empty patches of both conditions at 4 days. 
However, only in the presence of VEGF-releasing patches the VLD increased 
significantly at 14 and 28 days after implantation (Fig 4A-B, border). VEGF-expressing 
patches induced the formation of a mature capillary network with a physiologically 
branched morphology and the majority of new vessels were tightly associated with 
pericytes (Fig 4C). Moreover, no growth of aberrant structures was observed at either 
of the three time points, as expected with the delivery of controlled VEGF levels. Taken 
together, these results indicate that only VEGF-expressing patches have the ability to 
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efficiently induce safe and mature angiogenesis in an avascular volume placed at a 
significant distance from the engineered patch itself. 
 
Fig 4 Induction of angiogenesis in the underneath empty collagen scaffold. A) Quantification of vessel 
length density (VLD) in the center and border area of the empty scaffold sutured beneath patches 
generated by either the Naïve or VEGF cells at 4, 14 and 28 days after implantation (image analysis on 6 
random fields per area and per samples, n= 4 samples/condition; **p<0.01;***p<0.001. B) 
Representative images of blood vessel ingrowth in the center and border areas of the empty scaffolds 
28 days after implantation, assessed by immunofluorescence for CD31 (red). Dashed line outlines the 
area of the empty scaffold which was in contact with the host tissue (size bar=20 µm). C) Representative 
images of blood vessel maturation in the inner area of the empty scaffolds sutured beneath Naïve (left) 
or VEGF (right) patches 28 days after implantation, assessed by immunofluorescence staining for cell 
nuclei (DAPI; blu),  endothelial cells (CD31; red), pericyte (NG2; green) and smooth muscle cells (SMA, 
cyan); (size bar= 20 µm). 
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3.5 In vivo cell survival and migration. 
To assess the functional consequences of the observed vascular ingrowth, we 
evaluated the survival of the human ASC seeded on the patches. After 28 days in vivo, 
control patches contained a lower amount of engrafted human cells compared to 
VEGF-expressing patches (Fig. 5A). Quantification of human cells (identified as staining 
positive for the Human Nuclei_HuNu antigen) cells showed that the density of human 
ASC in the presence of VEGF expression was significantly greater than in control 
conditions, with an 11-fold increase (Fig. 5B). Interestingly, the absolute cell density of 
VEGF-expressing ASC was similar to the one measured before implantation (Fig. 1B), 
showing that VEGF expression completely prevented the cell loss that took place in 
control conditions instead. Most of the implanted cells were retained inside the patch, 
with very low cell migration in the area of the empty scaffold just next to the patch 
(Fig. 5C-D). No human cells were detected in the distal portion of the empty scaffold as 
well as in the surrounding host tissue in any condition. After 28 days in vivo, most of 
the implanted cells did not differentiate into a vascular lineage, as human cells could 
not be observed inside the vessel basement membrane, identified by laminin, which 
defines the limit between vascular cells (endothelium and pericytes) and the 
surrounding tissue (Figure 5E). Blood vessels were therefore essentially of mouse 
origin. Lastly, only very few implanted ASC were proliferating after 28 days in vivo, with 
no difference between naïve or VEGF-expressing cells, as shown by the quantification 
of human cells positive for Ki-67 (Figure 5F). 
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Fig. 5 In vivo cell engraftment and migration. A) ASC survival at 28 days was assessed by 
immunofluorescence staining for human nuclei (HuNu, in red) while all nuclei were visualized by DAPI 
(blue). White arrows indicate human cell nuclei in the naïve (left) and VEGF (right) patches (size bar 
20µm). B) Quantification of human cell density in the naïve and VEGF patches at 28 days (image analysis 
on 6 random fields per sample; n=2 4 samples/condition; ***p<0.001) C) (left): representative low-
magnification image of specific human nuclei (red) and DAPI (blue) staining in the VEGF patch at 28 
days. The white line represents the border between the patch and the empty scaffold (size bar=200µm). 
The small panels show higher magnification images of the areas in the white squares in the patch (top) 
and in the empty scaffold (bottom) (size bar=20µm). D) Quantification of human cell density at 28 days 
in the empty scaffold area below the naïve and VEGF patches (image analysis on 6 fields acquired 
randomly within 100 µm from the border line; n= 4 samples/condition). E) Representative images of 
immunofluorescence staining for human cells (in red), VE-Cadherin (in green), laminin (in grey) and DAPI 
(in blue) of patches generated by Naive or VEGF-expressing ASC after 28 days in vivo (size bar=20µm). F) 
Graph representing the percentage of human cells that are proliferating after 28 days in vivo in patches 
generated by Naive or VEGF-expressing ASC (image analysis on 6 random fields per sample; n=4 
samples/condition; no statistic difference). 
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4 Discussion and conclusions 
In this study, we showed that a patch seeded with a purified population of transduced 
adipose tissue-derived progenitor cells could function not only to attract intrinsic 
vascularization, but also as a device for delivery of controlled VEGF levels to induce 
extrinsic angiogenesis. 
Several strategies have been investigated in the past years to promote angiogenesis 
for the treatment of ischemic diseases or the rapid vascularization of engineered tissue 
implants. The successful generation of in vitro engineered substitutes (e.g. skin, bone, 
fat and muscles) cannot be translated clinically if a prompt in vivo vascularization 
strategy is not envisioned to allow implanted cell survival, assuring their function also 
upon implantation (26). Efficient vascularization of engineered tissues is particularly 
important in the case of critical-size (several mm-thick) constructs. The most 
commonly adopted strategy consists in pre-vascularizing the engineered tissues by co-
culturing mature or progenitor endothelial cells with mesenchymal stem cells or 
perivascular cells (27) or by the use of isolated (28) or pre-formed vessels (29). 
Moreover, the use of several biomaterials functionalized to release pro-angiogenic 
factors is an alternative promising method that is under investigation (30)(31). 
Our approach, based on the long-term over expression of VEGF from implanted cells, 
favors the recruitment of blood vessels from the host, guaranteeing already after 4 
days upon implant a dense vascularization of the entire cell-seeded construct (Fig. 3). 
On the opposite, patches prepared with naive ASC showed a few endothelial 
structures after 4 days: the fact that these were predominantly seen in the center of 
the patch, rather than at the border with the host tissue, suggests that these early 
68 
 
structures may depend on the few endothelial cells present in the ASC populations 
(Fig. 2F). Notably, the higher vascular density in VEGF patches compared to naïve ASC 
was maintained at 14 days, suggesting that VEGF expression was necessary for 
effective vascularization of the engineered patch. 28 days after implantation, vascular 
density was not further increased in VEGF-ASC patches and the newly induced capillary 
networks were associated with normal pericytes, indicating that they have achieved 
maturation and stabilization, as well as that angiogenesis induced by controlled VEGF 
levels is a self-limiting, non-progressive process. Particularly attractive is the 
perspective to implement this angiogenic strategy for the generation of different 
engineered tissue substitutes (e.g. muscle, bone) by co-culturing VEGF-expressing cells 
with a suitable progenitor cell source (32). 
A consistent body of literature both in skeletal muscle and myocardium previously 
found that controlling the VEGF dose at the microenvironmental level, to express only 
therapeutic levels that induce efficacious and normal angiogenesis, is crucial to avoid 
the formation of aberrant structures, since VEGF remains tightly localized in the matrix 
around expressing cells (13,14,17). By correlating the production of VEGF with a FACS-
sortable marker, it is possible to select and purify specific populations that 
homogeneously express only a desired safe and effective level of VEGF (16). It is 
however possible that the specific microenvironment of the 3D patch, in terms of 
scaffold composition and newly deposited extracellular matrix, might influence the 
spatial distribution of produced VEGF. Therefore, future studies will be necessary to 
investigate both the possibility of avoiding FACS-purification and the therapeutic 
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outcome of delivering non-purified transduced ASC expressing heterogeneous VEGF 
levels. 
Beyond the ability to attract vascularization inside the patch, we hypothesized that a 
patch seeded with VEGF-expressing cells could also act as a factor-delivery device and 
induce angiogenesis in the surrounding tissue. To test this hypothesis, we sutured 
beneath the patch an empty collagen scaffold of critical size (7-mm thick and 8-mm 
diameter). At 4 days after implantation no vascular structures were observed in the 
inner part of the empty scaffold. Moreover the infiltration that was measured at the 
border was similar in the presence of both control and VEGF-expressing patches, 
suggesting no VEGF effect at this early time point. However, by 14 days a significant 
difference was observed in both regions of the empty scaffold: at the border vessel 
density increased 2- and 4-fold in the VEGF expressing conditions compared to naive 
(at 14 and 28 days, respectively), while at the center a striking 8- and 20-fold increase 
was observed in the VEGF-expressing conditions compared to naive (at 14 and 28 days, 
respectively). Remarkably, VEGF expression induced a similar vascular density both in 
the center and at the border by 14 days, whereas in its absence VLD in the center 
remained greatly lower than at the border at all time points. Furthermore, these 
extrinsic vascular networks reached maturation through association with pericytes, 
which is a necessary condition for their long-term persistence and functional efficacy. 
These observations indicate that: 1) VEGF diffused to the edge throughout the core of 
the empty scaffold, covering a quite unexpected distance from the source and guiding 
the recruitment of blood vessels from the host. 2) Sustained expression, ensured by 
the survival and the stable transduction of ASC with an integrating viral vector was 
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necessary to provide sufficient time for vessels to reach the core of the empty scaffold. 
In this experimental setup, ASC did not have a role in the formation of blood vessels, 
but they rather functioned as vehicle for VEGF delivery while embedded in the 
collagen scaffolds. 
The engineered ASC-based patch described here represents an innovative device for 
controlled VEGF delivery that could be implemented to different fields, among which 
the treatment of cardiac ischemia might be a particularly suitable application, due to 
its specific requirements. In this future perspective, ASC are widely considered an ideal 
cell source for cardiac applications (18). In fact, skeletal myoblasts have been 
previously investigated as an attractive cell source for cardiac regeneration thanks to 
their capability to form contractile myofibers. However, they cannot acquire a 
cardiomyocyte phenotype and, most importantly, they form electrically active fibers 
that do not couple with the surrounding myocardium, causing dangerous arrhythmic 
events (33). On the other hand mesenchymal stromal cells, including ASC, do not form 
electrically active tissue and have been reported not to increase the risk of arrhythmias 
(34), providing therefore a more suitable cell source to deliver VEGF in the heart. In 
order to develop such an application, the functional properties of the extrinsic 
angiogenic potential described here would need to be further evaluated in an ischemic 
cardiac model to assess whether the sustained and controlled delivery of safe and 
effective VEGF levels to the ischemic tissue could improve perfusion, restoring local 
contractility and global cardiac function. Moreover, based on previous studies, the 
approach described here could also provide functional benefit through the further 
release of other paracrine factors, produced by ASCs, which can exert positive effects 
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on cardiomyocyte survival and on the ventricle remodeling after myocardial infarction 
(20).  
In conclusion, our findings provide a proof of principle for generating an efficient 
angiogenic patch that has the potential to be used clinically. However, before a 
possible clinical translation, alternative vectors should be considered, since 
retroviruses raise safety concerns of neoplastic transformation of transduced stem 
cells by insertional mutagenesis (35). Self-inactivating lentiviral vectors with chromatin 
insulator elements represent a valid solution thanks to their capability to express a 
transgene in a stable and sustained manner, but without the oncogenic potential of 
retroviral vectors (36) (37). 
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environmental distribution of Vascular Endothelial 
Growth Factor over-expressed by transduced progenitor 
cells  
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1 Introduction 
Over the last two decades, the concept of “therapeutic angiogenesis” emerged as a 
valid adjuvant treatment for patients affected by chronic cardiac ischemia following 
myocardial infarction (1)(2). Vascular Endothelial Growth Factor (VEGF)-based gene 
therapies have been extensively studied to boost the proangiogenic physiological 
response in order to restore the microvascular network, hence an adequate supply of 
oxygen and nutrients to the affected tissue (3); among the various isoforms, VEGF165 
has been determined as the most efficient in inducing functional and normal 
angiogenesis upon its over expression in vivo (4). Despite convincing pre-clinical 
studies, the efficacy of VEGF gene therapy, including the delivery of the gene for the 
isoform 165, has been highly questioned by controversial phase I/II clinical trial results 
(5). The inconsistent outcomes are mainly due to the low local transfection efficacy, 
resulting in limited amount and duration of protein expression (6). In fact, VEGF 
expression needs to be above a defined threshold and sustained for a period of at least 
four weeks to allow the maturation and the stabilization of the newly-formed blood 
vessels (7). A cell-based gene therapy approach might overcome these issues by 
transducing in vitro a suitable cell population to over-express the VEGF gene, ensuring 
a sustained release in vivo (8)(9). Nevertheless, intra-myocardial cell injection 
represents still the most used method in cell therapy, although is known to severely 
damage cells during the delivery leading to a poor survival (10)(11). In this context, 
epicardial delivery of in vitro engineered tissues has been shown to improve the 
survival of the implanted cells favoring their survival, favoring also the integration of 
the construct in the host myocardium (12)(13).  
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However, in order to fully exploit the therapeutic potential of the over expression of 
VEGF165 by a cell population, a tight control over the microenvironmental dose around 
each producing cell is necessary to avoid adverse effects, such as the growth of 
aberrant structures induced by very high doses (14)(15). In particular, it is well-known 
that the biological effect of the VEGF is tightly regulated through a balanced 
interaction with the Extracellular Matrix (ECM) proteins as perlecans, agrins and 
syndecans through the heparan-binding domain at the C-terminal (16). 
In the previous chapter, it has been reported the generation of an engineered VEGF 
expressing patch, by combining a tissue engineering strategy with a FACS-based 
purification technique that allows obtaining a population of retro-transduced adipose 
tissue-derived stromal cells (ASC) expressing defined and safe VEGF (17)(18). Although 
the cell purification step was optimized to be quite efficient, the procedure is still time-
consuming, relying also on an extensive cell monolayer expansion to achieve the 
needed number of cells. Because the effect of VEGF165 is strictly modulated by the 
interaction with the ECM proteins, it is rational to postulate that the biological 
composition of a scaffold could modulate the morphology of the blood vessels induced 
in vivo by a seeded cell population over-expressing the growth factor. In a previous 
publication, we observed that the collagen type I sponge (Ultrafoam) is characterized 
by a poor VEGF retaining ability (19). Therefore, in this study, we hypothesized that 
this collagen scaffold could act as buffer system at the microenvironmental level, 
diluting the very high concentrations of VEGF secreted by not purified ASC; this feature 
will prevent the formation of the toxic spots responsible for the growth of aberrant 
vascular structures upon implantation in vivo. In order to verify our hypothesis, we 
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compared the angiogenesis induced by the collagen-based patches with the one 
triggered by using a scaffold with a strong ability to bind the VEGF (19). We further 
tested the safety and the efficacy of the uncontrolled VEGF delivery through a 
collagen-based patch in a healthy nude rat heart model. Such proof of principle will 
open new perspectives on the use of the collagen scaffold as delivery tool and 
drastically reducing the procedure time and complexity avoiding as well the extensive 
monolayer-cell expansion needed to achieve an adequate number of cells. 
2 Materials and methods 
2.1 Cell transduction and sorting. 
Adipose tissue was obtained from healthy donors undergoing plastic surgery after 
informed consent and according to a protocol approved by the Ethical Committee of 
Basel University Hospital. Tissue was minced and digested with 0.15% type II 
collagenase (Worthington Biochemical Corporation) in PBS at 37°C under continuous 
shaking for 60 minutes. Released cells were strained through a 70-µm and a 100-µm 
nylon mesh, plated at a density of 105cells/cm2 and cultured in high-glucose DMEM 
medium with 10% FBS. After 4 days, cells were transduced with retroviral vectors 
expressing rat VEGF164 linked to a truncated rat CD8a through an Internal Ribosomal 
Entry Site (IRES) (18). At the first passage, after 12 days, transduced ASC were 
Fluorescence-Activated Cell Sorting- (FACS) based purified with a BD Influx Cell Sorter 
(BD Biosciences) with a gate determined by a reference clonal population of murine 
skeletal myoblasts expressing safe and specific VEGF levels (17,18). Three different cell 
groups were generated: NAÏVE ASC as control (I) and cells expressing specific (SPEC 
ASC) (II) or uncontrolled (ALL ASC) (III) levels of VEGF. 
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2.2 Generation of the EGG WHITE (EW) scaffold  
Chicken (Gallus gallus domesticus) eggs were collected freshly, not later than two first 
days of laying, broken manually and EW was deliberately separated from yolk without 
piercing the yolk. EW solution was then freeze-dried (Christ, Alpha 1–2 LD), milled to 
fine powders and kept in a freezer. The powder was later dissolved (6%, w/v) in acetic 
acid 2 M (Merck) and vacuum-degassed to remove air bubbles. Followed by molding 
the solution into 24-well plates, they were stored at 4 °C for 3 h. The samples were 
then freeze-dried overnight to form three-dimensional (3D) scaffolds EW scaffolds 
were subsequently cross-linked at 4 °C overnight using biocompatible, zero-length 
chemical crosslinker N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC, 30 mM, 
Sigma-Aldrich) in presence of N-Hydroxysuccinimide (NHS, 30 mM, Sigma-Aldrich). 
Crosslinking reaction was performed in 4-morpholineethanesulfonic acid (MES, Sigma-
Aldrich) buffer (50 mM, pH 5.5) in 70% ethanol.  For sterilization, scaffolds were 
thoroughly washed with double distilled water, followed by sterile PBS and 70% 
ethanol for 24 h each. Prior cell seeding scaffolds were incubated in culture media 
overnight.  
2.3 Physical characterization of the sponges 
Structure and morphology of EW and collagen scaffolds were evaluated using a 
scanning electron microscope (SEM, FEI Nova NanoSEM 230, USA). Lyophilized samples 
were first sprayed with gold and then observed at an operating voltage of 15 kV. 
Average pore size of samples was calculated from at least 300 measurements on SEM 
micrographs using Image Analyzer software (Image J 1.44p by NIH). Since the density 
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(ds) and average protein density (dp, 1.3 g.cm-3)(1) of EW and collagen scaffolds are 
known, the porosity of scaffolds was measured according to the following equation:  
Porosity (%)=(((d_p-d_s))/d_p )×100. 
Biomechanical testing were performed to assess the compressive module and the 
equilibrium swelling properties. Uniaxial compression assays were performed on pre-
hydrated (24 h at 37 °C in PBS) cylindrical scaffolds (12 mm in height and 6 mm in 
diameter) using a HCT-25/050 Zwick/Roell mechanical tester at 25 °C at a crosshead 
speed of 1.3 mm s-1 and 50% of the final strain level. Compressive modulus of EW and 
collagen scaffolds were determined using the tangent slope of the stress-strain curve. 
Four distinct samples were studied in triplicate for each group of scaffolds. Swelling 
properties of samples were determined at 37 °C in PBS for 24 h using gravimetric 
method. Lyophilized samples were first soaked in PBS, then blotted with a filter paper 
to remove excess liquid. Using the swollen (Ws) and dry (Wd) weights of scaffolds, the 
swelling ratio was calculated using the following equation:  
Swelling ratio (%)=(((W_s-W_d))/W_s )×100.  
Each swelling experiment was perfomed in quadruplicate and data presented as 
average and standard deviation.  
2.4 Generation of the patches 
For the generation of the patches, naïve, SPEC and ALL ASC were cultured on 8mm-
diameter and 3mm-thick collagen (UltrafoamTM, Avitene) or EW scaffolds at the 
density of 20 x 106 cells/cm3 (corresponding to 2.2 x 106 cells per scaffold). By using a 
perfusion-based bioreactor cells were perfused at a flow rate of 3 ml/min during the 
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cell-seeding phase (18 hours) and subsequently cultured at 0.15 ml/min for the 
following 5 days.  
2.5 Implantation in nude rat model 
To investigate the in vivo angiogenic potential of the engineered tissues based on 
collagen or EW, they were implanted ectopically (in subcutaneous pockets) or 
orthotopically (on healthy hearts) in 10-week-old male nude rats (Hsd: RH-rnu/rnu, 
Envigo RMS). In the ectopic model, half of the patches used for histological analysis 
(3/6) were sutured to cell-free (7 mm-thick) type I collagen scaffolds (as previously 
described in Chapter II, section 1 and 2.2). This served as clean systeml to investigate 
the extrinsic angiogenic potential of ASC expressing heterogeneous VEGF levels.  
Animals were treated in compliance with Swiss Federal guidelines for animal welfare 
and all procedures were approved by the Veterinary Office of the Canton Bern (Bern, 
Switzerland) and conform to the Directive 2010/63/EU of the European Parliament.  
In the ectopic model, nude rat were anesthetized by inhalation using a mixture of 
oxygen (0.6 L/min) and isoflurane (3 vol %). Samples (four per animal) were implanted 
in independent subcutaneous pockets in the back of the rat. At 7, 14 and 28 days post-
implantation, animals were anesthetized by intraperitoneal injection of a mixture of 
Ketamine (100 mg/Kg) and Xylazin (10 mg/Kg) prior sacrifice by total body vascular 
perfusion of 1% paraformaldehyde (PFA). To investigate the vascular perfusion, some 
rats were intravenously injected with 250 μl of 1 mg/ml FITC-conjugated Lycopersicon 
esculentum lectin (Vector Laboratorie) each and 4 minutes later the tissues were fixed 
by vascular perfusion of 1% PFA and 0.5% glutaraldehyde in PBS pH 7.4.  
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The harvested constructs were further fixed in PFA 0.5% for 5 hours and leaved in 30% 
sucrose solution overnight before embedding in Optimal Cutting Temperature (OCT) 
compound (Sakura Finetek) and frozen in isopentane vapors cooled in liquid nitrogen. 
For real time RT-PCR and ELISA assays rats were euthanized with CO2, samples 
collected and immediately frozen in liquid nitrogen and stored at -80° C for further 
processing.  
In the orthotopic model, rats (about 400 g weight) were intubated and continuously 
ventilated with a mixture of oxygen (0.6 L/min) and isoflurane (3 vol %). After a 
conservatively dissection of thorax muscles (3 layers) collagen-based engineered 
constructs were fixed on the left ventricles with 2 sutures. Transthoracic 
echocardiograms was performed on rats under controlled anesthesia (at 1-1.5 vol % 
Isoflurane for maintenance) and spontaneous respiration at 7 and 28 days post 
implantation using a Vevo 2100 Ultrasound machine (VisualSonics). At 28 days rats 
were sacrificed and hearts collected and immediately embedded in OCT as described 
before. 
2.6 In vitro VEGF quantification by ELISA assay.  
 To assess the VEGF binding capacity on different substrates, patches made by naïve 
ASC (n=5), cell-free collagen (n=5) and EW scaffolds (n=4) were incubated for 4 h at 37° 
C with 4 ml of culture medium, conditioned by monolayer-expanded ALL cells, 
containing 1.977 ± 0.36 ng/ml of rVEGF164. The amount of rat VEGF164 was quantified 
both in the supernatants and in the samples following two rinsing steps in PBS. Fresh 
culture medium with no VEGF supplementation was used as a control.  
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VEGF retention was also quantified in patches after 5 days of culture (n=4 per 
condition) or following in vivo implantation (n=3 per condition).  
The VEGF concentration was measured by an ELISA kit (DuoSet, R&D Systems) 
according to manufacturer’s instructions. 
2.7 Quantitative real-time reverse transcriptase polymerase chain reaction 
(RT-PCR) 
In vitro collagen or EW based patches were digested in TRI-Reagent (Sigma); total RNA 
was isolated following an adaptation of the method of Chomczyński and Sacchi (20). 
cDNA was reverse-transcribed from mRNA with the Omniscript Reverse Transcription 
kit (Qiagen) at 37 C° for 60 min. Quantitative real-time PCR (qRT-PCR) was performed 
with TaqMan® Assays master mix (Life Technologies) using a ABI 7500 Real-Time PCR 
system (Applied Biosystems). To investigate the expression of exogenous rVEGF gene 
we measured mRNA expression levels of the IRES sequence contained in the gene 
construct. Specific sets of primer and probe sequences were designed with Primer 
Express software 3.0 (Applied Biosystems, Zug, Switzerland):  
Forward: 5′-GCTCTCCTCAAGCGTATTCAACA;  
Reverse: 5′-CCCCAGATCAGATCCCATACA;  
Probe: 5′-FAM-CTGAAGGATGCCCAGAAGGTACCCCA-TAMRA. 
All primers were used at 400nM. Reactions were performed in triplicate for each 
template, averaged, and normalized to expression of the hGapdh housekeeping gene. 
2.8 Histology 
All histological analyses have been performed on frozen sections. For 
histomorphological evaluation, sections were stained with hematoxylin and eosin 
(H&E) and Masson Trichrome according to standard protocols. Color images were 
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acquired with Olympus BX63 microscope (Olympus). For immunofluorescence 
analyses, cryosections were incubated for 1 hour in 0.3% Triton X-100 and 2% normal 
goat serum in PBS, and then for 1 hour in the following primary antibodies: (1) anti-
CD31 (AbDSerotec) diluted at 1:100, (2) anti-NG2 (Millipore) at 1:200, (3) anti-α 
Smooth Muscle Actin (Sigma-Aldrich) at 1:400, (5) anti-Ki-67(AbCam) at 1:200, (6) anti- 
Human Nuclei (MAB1281 Millipore, Germany, Antibody Registry identifier AB_94090) 
at 1:100, anti-fibronectin (AbCam) at 1:200 and anti-agrin (AbCam) at 1:100. All 
secondary antibodies were used at 1:200 for 1 hour incubation (Life Technologies). For 
CD73, CD105 and rCD8 staining, were used primary antibodies conjugated with PE APC 
and FITC fluorochromes respectively (Biolegend). Nuclei were stained using DAPI 
(Invitrogen) for 1 h. All antibodies were diluted in 0.3% Triton X-100 and 2% normal 
goat serum in PBS. 
2.9 Vessel measurements 
Vessel length density (VLD) and diameters were measured on 10 m-thick frozen cross-
sections stained for endothelial cells (CD31+ cells) of implanted patches or the 
surrounding myocardium. Briefly, VLD was measured in 5–10 fields per patch/heart (at 
least n = 3 per condition) by tracing the total length of blood vessels and dividing it by 
the total area of the field of interest (mm of vessel length/mm2 of surface area).  
Vessel diameters were randomly measured on six acquired images per sample (at least 
3 per condition). Around 450 total diameter measurements were obtained from three 
independent experiments per condition.  
All analyses were performed using the CellSens software (Soft Imaging System). 
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2.10 Human cell quantification 
In vivo implanted human cell density was assessed at 0 (pre-implants) and 28 days post 
implantations. Six representative fluorescent images per sample (n=4 samples per 
condition) were acquired with 20x magnification with an Olympus BX63 microscope 
(Olympus) on patch cross-sections. Human nuclei positive cells were counted using 
ImageJ 1.47 software (Research Service Branch). 
2.11 Statistics 
Data were analyzed with the statistical software Prism 5.0a (GraphPad). Data are 
presented as means ± standard deviation. Comparison between groups was performed 
using a one-way ANOVA with Bonferroni correction. P<0.05 was considered 
statistically significant. 
3 Results 
3.1 Delivery of uncontrolled VEGF levels induces normal, mature and 
functional angiogenesis  
To prove our initial 
hypothesis, we first 
assessed whether 
transduced ASC 
expressing uncontrolled 
(ALL) VEGF levels 
following 3D culture on collagen-based sponges could induce normal and efficient 
angiogenesis, in a subcutaneous rat model, similarly to cells purified to express only 
safe doses of the protein. During monolayer-culture, only SPEC and ALL ASC produced 
rat  
Supp. fig 1 A) rVEGF production by SPEC and ALL ASC-based patches 
after 5 days of dynamic culture (n=4) B) In vitro quantification of cell 
proliferation and density (C) in  collagen-based patches generated by 
naïve, SPEC or ALL  ASC after 5 days of culture.(n=3). 
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Fig. 1 Angiogenesis induced by collagen-based patches in an ectopic rat model. A) Representative 
images of blood vessels ingrowth in patches generated by naïve, SPEC and ALL ASC after 7 and 28 days in 
vivo (size bar =25µm). B) Quantification of vessel length density (VLD) in the naïve and both VEGF 
expressing patches at 7 and 28 days upon implants (n= 4 samples/condition; ***p<0.001). C) 
Representative images of newly formed blood vessels stained for maturation markers at 28 days in SPEC 
and ALL patches.  Cell nuclei are stained with DAPI (blue), endothelial cells with CD31 (red), pericytes 
with NG2 (green) and smooth muscle cells with SMA(cyan) (size bar=20 µm). D) Representative images 
of growing blood vessels at 7 and 28 days in ALL patches. Proliferating cells are stained with Ki-67 (cyan) 
and blood vessels with VE-Cadherin (red) (size bar=20 µm) E) Quantification of proliferating endothelial 
cells at 7 and 28 days in vivo (n=3 per condition; ***p<0.001). F) Newly induced blood vessel in SPEC and 
ALL ASC patches stained by intravascular FITC-fluorescent lectin injection at the moment of sacrifice at 
28 days (DAPI in blue; lectin in green; CD31 in red; size bar=20 µm). G) Ratio of perfused (lectin positive) 
vessels normalized to the total amount of vessels found in SPEC and ALL patches at 28 days post 
implantation (n=3). 
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VEGF in a similar amount (36.9 ± 7.3 and 34.5 ± 10.1 ng / 106 cells, respectively; Supp. 
Fig 1A). Importantly, VEGF expression did not affect the in vitro proliferation of human 
ASC, which resulted to be quite low in all experimental groups (Supp. Fig 1B). The cell 
density after 5 days of culture resulted also to be similar in all conditions (Supp. Fig 
1C). Upon implantation, collagen-based patches generated by SPEC or ALL ASC showed 
an increased blood vessel ingrowth both at 7 and 28 days compared to control (Fig 1A). 
The quantification of vessel length density corroborated the histological observations 
by showing a significant persistent ~3-fold increase in VEGF-expressing ASC compared 
to NAIVE cells at 7 and 28 days (Fig 1B). Although no statistical significance was found 
in the VLD of patches generated by SPEC and ALL ASC within the same time point, a 
physiological regression of the number of vessels was observed from 7 to 28 days. 
Notably, we did not detected vessels displaying abnormal size or aberrant phenotype 
in the patches generated by ASC secreting heterogeneous VEGF levels at any time 
points. The newly-formed capillaries (Fig 1C, Red) in both SPEC and ALL ASC-based 
patches displayed a mature morphology with normal size and pericytes coverage (Fig 
1C, green) and a thick layer of SMA positive cells (Fig 1C, Cyan) surrounding arterioles. 
Interestingly, at day 7 the blood vessel morphology induced by the ALL ASC patches 
was normal with no detection of proliferating enlarged vasculature structures (Fig 1D). 
At 28 days, the capillaries formed are in large part still present with very few 
endothelial cells dividing, which is most likely representing a complete shutdown of 
the angiogenesis process (Fig 1E). The amount of proliferating endothelial cells was 
similar in ALL and SPEC at both time points and statistically significant decreased at 28 
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days (Fig 1E). Moreover, the majority of the induced blood vessels were functionally 
connected to the host network, as showed by the co-localization of the green 
fluorescent signal (perfused circulating lectin) with the CD31 staining and the 
quantification of the ratio of the perfused versus the total amount of vessels (Fig 1F-G). 
Taken together these results showed that collagen-based patches efficiently prevented 
the formation of aberrant structures also when ASC were not FACS-purified to express 
safe VEGF levels. 
3.2 Implanted human cell did not directly participate to the vessel 
formation 
Implanted human ASC were homogeneously present throughout the patches, 
however, while the naïve ASC appeared mainly scattered, the cells expressing both 
specific and heterogeneous VEGF levels were denser (Fig 2A). In the VEGF-based 
constructs, an increased number of implanted cells were observed within the patch 
compared to control constructs. Quantification of cell density before and after 
implantation confirmed the histological observation: while the initial cell density was 
maintained in the VEGF-expressing patches at 28 days, the NAIVE cells significantly 
decreased in number (Fig 2B). The amount of rat VEGF entrapped in the implants 
generated by both SPEC and ALL was significantly higher than in the naïve samples at 7 
days and decreased at 28 days, resulting to be similar to the control value (Fig 2C). 
Nevertheless, the expression of the IRES sequence (contained in the viral vector) was 
still detectable at 28 days, suggesting still an ongoing expression of exogenous VEGF 
(Fig 2D). Since ASC contain cell subpopulation capable to differentiate into 
endothelial/mural cells (21), their in vivo fate was investigated. In VEGF-patches, the 
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majority of the implanted cells resulted to be mainly close to but not embedded in the 
basal lamina of the newly formed capillaries (Fig 2E).  
 
Fig. 2 Implanted cell fate in ectopic rat model. A) Representative immunofluorescence images of 
human cell distribution after 28 days in vivo in patches generated by naïve, SPEC and ALL ASC. Human 
nuclei were visualized in green (HuNu) and all nuclei in blue (DAPI) (size bar 20 µm). B) Human cell 
density in patches generated by naïve, SPEC and ALL ASC at day 0 (pre –implants) or 28 (post-implants) 
in vivo (n=4, ***p<0.001). C) rVEGF quantification in naïve and VEGF-expressing constructs after 7 and 
28 days in vivo. (*p<0.05; ***p<0.001). D) RT-PCR analysis of IRES mRNA expression in SPEC and ALL 
constructs at 28 days in vivo presented as fold increase compared to the Control (naive patches). E) 
Representative immunofluorescence images for human cells (HuNu in green), VE-Cadherin (in red), 
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laminin (in grey) and DAPI (in blue) in patches generated by SPEC or ALL ASC after 28 days in vivo. White 
arrows indicate human cells embedded in the endothelial basal lamina (size bar=20µm). F) Percentage 
of human SPEC or ALL ASC with a role of mural cells (n=3 sample/condition). G) Immunofluorescence 
images for mesenchymal markers (CD73 in red; CD105 in cyan) in human transplanted cells identified 
with the rat CD8 (green) and DAPI (blue) at 28 days in vivo (size bar=25µm). 
The number of mural cells of human origin was rather low and similar in the patches 
generated by either SPEC or ALL ASC (Fig 2F). The great majority of the implanted 
human ASC maintained the expression of the typical mesenchymal membrane markers 
as CD73 and CD105 at 28 days, suggesting that most of the cells retained the stromal 
phenotype (Fig 2G). Taken together these results showed that ASC per se might not 
have a key role in the normalization of abnormal structures.  
3.3 Collagen-based scaffolds allow VEGF diffusion  
To verify that the specific scaffold composition regulates alone the diffusion or not of 
VEGF, we compared the type of vessels formed in vivo by culturing ASC expressing 
heterogeneous protein levels on sponges made of either collagen or Egg White (EW). 
While collagen is known to not bind 
the VEGF164, EW has shown to have a 
high affinity to bind proteins 
including this specific isoform (19). By 
scanning electron microscopy 
imaging, the collagen and EW 
scaffolds displayed an analogous 
architecture with similar percentage 
of porosity and pore size (Fig 3A-B). 
The two sponges showed similar 
Supp. fig 2 A) Representative images of Haematoxylin 
and Eosin (H&E) staining and Masson Trichrome (MT) 
staining of naïve ASC-based patches after 5 days of 
dynamic culture (size bar=25 µm). B) Amount of rVEGF 
retained by collagen scaffolds either alone (COLL) or 
with extracellular matrix (ECM) deposited by naïve ASC. 
(n=5 per condition). C) Characterization of extracellular 
matrix composition of COLL- or EW- based patches 
generated by naïve ASC after 5 days of in vitro culture: 
DAPI  (blue), agrin (green), fibronectin (FN, red) (size 
bar=20 µm). 
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swelling and degradation properties (Fig 3B). When incubated with VEGF164 containing 
medium, collagen per se did not resulted positive for VEGF immunofluorescence 
staining,  
 
 
Fig. 3 In vitro characterization of different scaffold composition. A) SEM images of the porous 
architecture typical for collagen (COLL) and Egg White (EW) scaffolds (size bar=100 µm). B) Structural 
features of COLL and EW sponges. C) Immunofluorescence images for rVEGF (in red) bound to COLL or 
EW scaffolds (identified in blu by a high exposure time; size bar=20µm). D) Quantification of rVEGF 
trapped in the scaffolds (bound to the scaffold) and in the supernatants (not bound) after 4 hours of 
incubation in ALL ASC-conditioned medium. (n=5 for COLL, 3 for EW ***p<0.001). E) In vitro IRES mRNA 
expression in collagen or EW scaffolds seeded with ALL-ASC (n=3 per experimental group) has been 
normalized on the relative expression of hgapdh and presented as fold increase compared to the control 
(CTRL). F) Quantification of in vitro rVEGF present in COLL and EW sponge-based patches generated by 
ALL ASC after 5 days of culture (n=3 per condition; *p<0.05). 
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whereas EW showed a detectable amount of protein bound on the scaffold surface 
(Fig 3C). The quantification of rVEGF confirmed that most of the protein was not bound 
to the collagen scaffold, since it was found almost entirely in the supernatant. On the 
contrary EW-based sponges retained the 25% of the available VEGF (Fig. 3D). 
Importantly, after 5 days of perfusion-based culture ASC deposited a poor amount of 
extracellular matrix (ECM) mainly detected to the immediate surrounding area of the 
cells (Supp. Fig 2A). The ability of the naïve-based patches in retaining the VEGF was 
similar to the collagen sponge alone (Supp. Fig 2B). The ECM was deposited by naïve 
ASC in a scattered way both in collagen and EW sponges and was composed similarly 
by low amount of VEGF-binding proteins as agrin and fibronectin (FN). Agrin was 
indeed mainly undetectable, whereas FN was low and mainly expressed within the 
cytoplasm (Supp. Fig 2C).  Moreover, although the expression of VEGF at the mRNA 
level of ALL-ASC after 5 days of culture in EW-based sponges was similar to that 
obtained in the collagen sponges (Fig 3E), the total amount of VEGF entrapped in the 
EW-construct was ca. 5-times superior (Fig 3F). These observations further confirm the 
ability of EW scaffold to bind the VEGF. 
3.4 The scaffold composition controls the type of angiogenesis induced: 
normal versus aberrant. 
When ASC expressing not controlled VEGF levels were cultured on EW-based scaffolds, 
numerous aberrant large blood vessels, a general dysfunction of pericytes and 
inhomogeneous coverage of smooth muscle cell layers were detected after 14 days in 
the rat subcutaneous pockets (Fig 4 white arrow). On the contrary, angiogenesis 
induced by the same donor cells expressing the same heterogeneous VEGF levels but 
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seeded on a collagen scaffold displayed a normal phenotype (Fig 4 ALL COLL, left 
column). Extended quantification of vessel diameters showed that the presence of 
large-in-size structures  
 
Fig. 4 Angiogenesis induced by egg white-based patches in ectopic rat model. Representative images 
with the relative distribution of vessel diameters of newly formed blood vessels in COLL or EW scaffold 
seeded with ALL ASC or in SPEC EW-based patches at 14 days upon implantations. Cell nuclei are stained 
with DAPI, pericytes with NG2, endothelial cells with CD31and smooth muscle cells with SMA. White 
arrows identify abnormal vessel structures (size bar=50 µm). 
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has a higher preponderance in 
EW-patches compared to COLL-
constructs. These enlarged 
structures were consistently 
observed throughout the three 
replicates examined. Remarkably, when EW scaffolds were seeded with ASC expressing 
controlled VEGF levels, no aberrant structures were formed (Fig 4, SPEC EW, right 
column) and the vessel diameter distribution was similar to the one measured in the 
collagen-based patches (Fig 4). Importantly, the implanted human cells were uniformly 
distributed both in the collagen and in the EW sponge after 14 days in vivo and in a 
similar density (Supp. Fig 3 A, B).  
3.5 Collagen-based patches act as efficient and safe VEGF delivery systems 
The extrinsic angiogenic potential and the safety of the collagen-based patches 
releasing uncontrolled VEGF levels were assessed in both ectopic and orthotopic 
model of healthy myocardium. In rat subcutaneous pockets the angiogenesis was 
induced efficiently in the 7-mm-thick-collagen sponges with a higher vessel length 
density when ALL and SPEC VEGF-expressing patches were used compared to naive 
cells (data not shown). These results confirmed the previous extrinsic angiogenesis 
observed in mice when controlled VEGF levels were used (described in Chapter II, 
Supp fig 3. A) Representative images and B) quantification of 
human cell density in COLL- or EW-based patches generated 
by ALL ASC at 14 days in vivo (n=3; no statistically significant 
difference was found) 
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section 3.4) and further demonstrated the efficacy of ALL ASC to induce normal 
angiogenesis in the surrounding area. 
In healthy heart model, implants were found still in place on the top of the left 
ventricle after 28 days (Fig 5A H&E). However, while the cell-free collagen scaffolds 
showed no  
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Fig 5 Collagen-based patches following implantation on healthy rat hearts. A) Representative images 
of Haematoxylin and Eosin (H&E) and Masson Trichrome (MT) of heart cross-sections implanted with 
cell free (EMPTY), naïve and ALL ASC collagen-based patches (size bar=500 µm). B) Representative 
images of human cell survival (in green) and patch vascularization at 28 days (DAPI blue, CD31 red, NG2 
green, SMA cyan, size bar=50 µm). 
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important modification, the patches generated by ASC appeared to be quite 
remodeled, with a significant invasion of host cells and newly deposited extracellular 
matrix forming a fibrotic tissue within the constructs (Fig 5A, MT). Remarkably, human 
cells were still detectable in both naive and ALL ASC patches after 28 days. While cell-
free scaffolds and naive ASC-based constructs were invaded by few blood vessels, 
VEGF-expressing patches were highly vascularized with mature blood vessels reaching 
the center of the implants. In the patch expressing heterogeneous VEGF levels, the 
abundant and newly formed vessels displayed a normal and mature morphology and 
consisted in both arterioles, surrounded by smooth muscle actin, and capillaries with 
the typical coverage with pericytes (Fig. 5B bottom panel). No abnormal vessel 
enlargements or morphology were observed in collagen-based patches generated by 
ASC releasing uncontrolled VEGF levels. Of note, the blood vessels significantly 
increased in the underlying myocardium only when VEGF expressing patches were 
used (Fig 6A). The quantification of the vessel length density showed a ~ 1-fold 
increase of VLD in the VEGF expressing patches compared to the controls. This 
angiogenic effect was observed up to 500 µm depth in the underlying myocardium of 
the VEGF-expressing engineered constructs. 
The presence of the patches (either cell-free or cultured with naïve or VEFG- ASC) per 
se did not affect the functionality of the heart compared to the sham condition within 
a period of 28 days, as shown by the measurement of ejection fraction and fractional 
shortening recorded at 0 (pre-implantation baseline), 7 and 28 days post implantation. 
Taken together these results showed that collagen-based delivery of heterogeneous 
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VEGF levels induced an efficient and safe angiogenic process both in the patch itself 
and in the healthy surrounding myocardium, without impairing the heart contractility. 
 
Fig 6 Induction of extrinsic angiogenesis in the rat healthy myocardium. A) Representative images of 
capillary density of the rat myocardium in the area acquired beneath the patches. Nuclei are stained in 
blue (DAPI) blood vessels in red (CD31). White lines represent the boundary between the myocardium 
and the implanted patch (size bar=50 µm). B) Quantification of VLD in the host underneath myocardium 
(EMPTY, n=3; NAIVE n=3 ALL n=4; ***p<0.001). C) Heart functionality measured as percentage of the 
Ejection Fraction (EF, left) and Fractional Shortening (FS, right) in the experimental groups (SHAM n=6, 
EMPTY n=3, NAIVE n=3 and ALL n=9) at 0 (pre-implant) 7 and 28 days post implantation. 
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4 Discussion and conclusions 
In the present study, we demonstrated that a porous scaffold made of type I collagen, 
acting as a diffusion system, prevents the formation of toxic spots of VEGF caused by 
the uncontrolled overexpression of the protein from retro-transduced cells.  
Analysis of cell survival showed the importance to prompt vascularize the scaffold in 
order to supply enough nutrients to the cells. In fact, in the patch that does not 
express VEGF we observed a drop in the cell density, overall suggesting that a tissue 
engineering approach without an intrinsic proangiogenic stimulus could fail because 
the premature death of the tissue implanted. 
Efficacy in inducing angiogenesis is strictly modulated by the interactions between the 
VEGF and the extracellular matrix proteins; therefore, the biological effect, in 
particular the morphology of the new blood vessels, depends on the 
microenvironmental concentration to which are expose the next endothelial cells. In 
previous studies, a method based on the sorting of a population expressing only 
specific levels of VEGF has been tuned. Although the efficacy in preventing the 
formation of aberrant structures also in a 3D setting has been demonstrated, this 
method is not feasible for a translational approach because the high number of 
expansion and the in vitro manipulation required to achieve enough cells could affect 
their behavior. Recently, it turned out that a balanced co-delivery of VEGF and PDGF-
BB, which is responsible for the recruitment of the pericytes, normalized abnormal 
vasculature suggesting a key role of mural cells in modulating the biological effect of 
the VEGF (22). In this study we showed that a collagen sponge used as scaffold to 
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generate a 3D patch acts as deliver system by diluting the toxic spots forming around 
cells expressing high levels of VEGF. 
In particular this is possible on one hand because the inability of the collagen to retain 
the growth factor. On the other hand, the time of 3D perfusion culture (5 days) 
necessary to generate the patch is not sufficient for the cells to build a dense ECM. 
This concept is further support by the fact that the ECM produced by the ASC under 
perfusion lack completely of agrins, fibronectin (Supp. fig 2C) and perlecans (data not 
shown), which are the ECM proteins mainly responsible for the binding of the VEGF. In 
vivo it has been shown that in case of high levels of VEGF, aberrant structure growth 
within the first week and they became independent from VEGF signal continuing in 
proliferating. In this case, we observed inside the patch a normal angiogenesis 
proliferation at 7 days and any enlarged structures proliferating, although a sustained 
expression of the VEGF was maintained. ELISA assay confirmed a higher concentration 
of VEGF in the patches at 7 days in vivo as compared to the control, with a progressive 
decrease at long-term time point, as expected. In fact, although the viral construct is 
stably integrated in the genomic DNA, it is well-known that the promoter of the virus 
progressively becomes silenced in vivo due to the immune system recognition. 
Nevertheless, at 28 days RT-PCR analysis showed that it was still possible to detect 
copies of mRNA containing the IRES sequence, suggesting that ASC were still active in 
expressing exogenous VEGF. On the other hand, the effect on the endothelial cells 
decreased over a time leading to quiescence, where only few cells were still in the cell 
cycle. Based on these observations, we can speculate that the prevention of the 
growth of the aberrant structures is due mainly to the inability of the patch to retain 
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the VEGF, homogenizing the microenvironmental concentration. On the opposite 
when a scaffold that is able to efficiently retain the VEGF is used, we observed the 
growth of abnormal blood vessel with a spare dysfunction of the pericytes and a 
general increase in vessel diameters. Although the mechanism through this occurs has 
not been investigated, we can speculate that, once the blood vessels growth inside the 
patch within the first week attracted by the VEGF they get exposed to uncontrolled 
levels of VEGF. The blood vessels that meet high levels of VEGF grow abnormally, 
displaying the classical features of aberrant structures. Importantly, the collagen 
scaffold is able to prevent the growth of aberrant structures also when the patch is in 
contact with a highly vascularized tissue such as the myocardium. ALL patches not only 
do not cause aberrant angiogenesis but also increase the vascularization of the 
underneath tissue up to 500 μm, displaying an effective ability to provide an extrinsic 
proangiogenic stimulus. This could be a consequence of the diffusion capacity of the 
collagen. Future studies will aim to investigate the extrinsic angiogenic potential of 
these VEGF-expressing patches in chronic ischemic animal models and in particular for 
the treatment of the border zone of the infarct where there is a rarefaction of the 
microvasculature and the cardiomyocytes are not functional but still alive. It will be 
crucial to assess the VEGF capacity of diffusing through a fibrous scar tissue, present 
upon a myocardial infarction. Importantly, the functionality of the heart is not affected 
by the presence of the scaffold per se, further supporting the concept that this 
approach could be feasible in treating an ischemic myocardium. Further studies are 
also needed in order to deep investigate this aspect, focusing also on the paracrine 
effect that the ASC could have on the remodeling of the scar tissue. 
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In conclusion in this study, we demonstrated that composition of the scaffold in 
generating engineered tissues to deliver VEGF is a key to control the high potent 
angiogenic protein diffusion action, normalizing the microenvironmental concentration 
of the growth factor. 
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VEGF cell-based gene therapy is a promising approach to induce therapeutic 
angiogenesis; however, the delivery of the cell population and the control over the 
protein expression levels still represent major issues. In this research project, we 
showed the possibility to generate in vitro a protein delivery platform (patch) based on 
genetically modified ASC cultured on a type I collagen sponge. We demonstrated that 
collagen based patches could induce physiological growth of new capillaries both 
within the construct itself and in the surrounding tissue also when ALL ASC were used, 
thanks to the poor affinity of the scaffold for VEGF. These promising results suggest 
numerous future studies. On one hand, it is crucial to investigate the effects of the 
angiogenesis induced by the patch also in animal infarction models in terms of micro-
revascularization and eventually rescue of cardiomyocytes in low perfused areas of the 
hibernating myocardium. On the other hand, a specific study should be designed in 
order to understand whether such a diffused pro-angiogenic signal is enough to 
stimulate also the opening of the coronary collateral circulation (1) as already 
demonstrated in the hind limb ischemia model with other approaches (2). 
Concerning the therapeutic potential, it is of primary interest to understand the limit 
of the VEGF diffusion from the patch placed on the epicardial surface of the heart into 
the myocardium. In fact, in cases of large infarction the ischemia can extend to the 
endocardium, damaging also the inner lining of the heart (trans-mural infarction). In 
this circumstance, it could be useful to support the action of the epicardial patch with 
several adjuvant intramyocardial injections of cells pre-organized in gels. In alternative, 
an attractive perspective derives from the possibility to exploit techniques that are 
used in cancer therapy to improve the diffusion of molecules through the ECM of solid 
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tumours, such as injection of proteases including trypsin, collagenase, hyaluronidas, 
metalloproteinase, relaxin and decorin (3)  
Beyond angiogenesis induction, VEGF-A is directly involved in other physiological 
processes of repair after MI, such as pro-survival, adhesion and homing of c-kit positive 
bone marrow derived cells and inhibition of cardiomyocyte apoptosis (4). Therefore, it 
is critical to determine whether the prolonged VEGF over-expression might improve or 
impair these processes in a post-infarction heart failure condition. 
Another important aspect, which should not be underestimated, is the use of ASC as 
delivery cell source; as briefly mentioned already in the discussion of the second 
chapter, ASC recently emerged as the “optimal” population in cell therapy for MI (5). 
Although in our experimental set-up we did not investigate any substantial paracrine-
mediated angiogenic effect, we could not exclude the possible release of other factors 
affecting the scar composition, thus its stiffness, and the cardiomyocyte survival. 
Therefore, beyond the angiogenesis induction benefits, it would be interesting to 
investigate the cardioprotective effects of the factors released by the cells, regarding 
in particular the remodeling of the scar tissue and the survival of remaining 
cardiomyocytes at the border zone. Taking in account that our patch guarantees the 
survival of the cells up to 28 days upon implantations, the paracrine effects could be 
greatly improved as compared to what has been observed with the intramyocardial 
injections.  
The final perspective of such study is undoubtedly to propose this model as adjuvant 
treatment for MI and start the first in human trial. The first “proof of principle” for the 
safety, in terms of survival after the treatment, and for the efficacy in triggering a 
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proangiogenic stimulus, has been evaluated in immunocompromised pre-clinical 
animal models. Moreover, functional data (2D echo, chapter III section 3.5) excluded 
any possible impairment by the scaffold on the normal contractile function of an 
healthy heart. However, beyond the necessity to investigate the therapeutic efficacy, 
major translational issues related to the safety and the scale-up of the model require 
deeper investigations. In particular, alternative gene vectors should be considered, 
since retroviruses raise safety concerns about neoplastic transformation. In this 
context, the new self-inactivating lentiviral vectors or new serotypes of AAV are valid 
solutions to be tested in our system (6). In this study the viral construct has been 
designed to be tested in rodent models; studies in larger animals (such as rabbit or 
pigs) will require increased size of the patch, with a consequent increment of the 
number of the cells needed. Therefore, an “ad hoc” study aiming at maximize the 
transduction efficiency of the new vectors will be necessary to limit the expansion of 
the cell population in vitro. In perspective, considering unessential the FACS 
purification step for the selection of safe VEGF expressing cells, the gene box for the 
CD8 marker could be replace by another growth factor in order to improve or 
accelerate the angiogenic stimulus (such as FGF-2 or PDGF-BB). 
Importantly, the generation of several mm-diameter patches for large animal models 
will require a strict collaboration with engineers to develop a scale-up of the 
bioreactor. Moreover, in vision of clinical application, controlled bioreactor-based 
culture systems need to be designed conforming to the good manufacturing practice.  
In parallel, the patch could be used as a “template” for the development of tissue 
engineering applications, where the prompt supply of oxygen and nutrients inside the 
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scaffold still represents a bottleneck for the survival of the implanted cells (7). 
Therefore, it will be appropriate to investigate the minimum amount of VEGF 
expressing cells needed to guarantee the fast vascularization of the patch, so that the 
remained space could be exploit for co-culturing a suitable cell population. In this 
context, the recent progresses in the field of stem cell biology offer several valid 
opportunities such as mature cardiomyocytes derived from embryonic or induced 
pluripotent stem cells, although the safety of these cell population still need to be 
addressed. This application could be further extended at other highly vascularized 
tissues, such as liver, skin and bone.  
In conclusion, this work represents an optimal model to investigate fundamental 
angiogenic mechanisms, but also the starting point for different translational medicine 
projects that will open new perspectives in the field of cardiac regenerative medicine 
and vascularization in tissue engineering. 
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